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Abstract 
 
Over the past thirty years there has been a dramatic improvement in the 
survival of children with congenital heart disease, and the vast majority can 
now expect to reach adulthood. However it is rare that a lesion can truly be 
described as "cured" even with everything that modern surgery can offer. 
Often lesions are palliated instead, and this subjects patients to a variety of 
complications in later life. These include residual haemodynamic lesions 
necessitating further surgical or percutaneous intervention, cardiac 
arrhythmia, and heart failure. All of these are potentially lethal, and result 
in a steady decline in survival, functional status and quality of life in later 
years. 
In order to care for these patients a new medical subspecialty has emerged - 
that of Adults with Congenital Heart Disease (ACHD). Although the provision 
of highly specialist management for this population has allowed many 
significant clinical improvements to be made, healthcare practitioners 
working in this field face significant challenges. The long term prognosis for 
these patients is uncertain, making it difficult to know how to counsel young 
people who wish for employment, a family, and a future. Whilst powerful 
tools for the non-invasive assessment of cardiovascular structure and 
function exist, their role in clinical decision making is often poorly defined, 
and the nature and timing of repeat intervention are frequently based on 
expert opinion rather than robust evidence from large well conducted 
clinical trials, and consequently the true benefit of such procedures is 
unclear. Furthermore, to my knowledge, there has never been a serious 
attempt to characterise outcomes in ACHD patients in Scotland.  
Because of the sheer heterogeneity of congenital cardiac conditions I 
decided to focus on outcomes in two distinct, relatively easily defined 
cohorts of adult patients with repaired congenital heart disease - patients 
with a systemic right ventricle, and patients with repaired Tetralogy of 
Fallot (TOF), both characterised by the presence of an abnormal right 
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ventricle. In chapter 3 I outline what is currently known about mortality and 
morbidity in each condition, based on what has been reported globally by 
other congenital cardiac centres. I then report the survival and adverse 
outcomes experienced by patients followed up by our centre: for patients 
with a systemic right ventricle in chapter 4, and for patients with repaired 
TOF in chapter 5. I assess these outcomes both in relation to the published 
literature internationally, and also to the general Scottish population. 
Finally, in chapter 6 I assess the clinical utility of parameters derived from 
cardiac MRI and cardiopulmonary exercise testing to establish whether this 
can improve clinical risk stratification for patients with repaired TOF.  
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Chapter 1 Introduction 
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1.1 Preamble 
 
Congenital heart disease is the commonest form of birth defect, with a 
reported incidence of 7-11 per 1000 live births. Furthermore, this appears to 
be increasing in the contemporary era, due to improved recognition and 
detection in infancy, and also improvements in neonatal intensive care 
(Marelli et al., 2014, Egbe et al., 2015, van der Linde et al., 2011).  
 Congenital heart defects vary greatly in their effect on circulatory 
function and physiology, and by extension survival. Mild defects may cause 
no appreciable clinical signs at all for many years, on the other hand more 
severe defects are ultimately lethal without urgent intervention. Until the 
second half of the 20th century such intervention was not possible, leading 
to a bleak prognosis for children with these more severe lesions. However 
phenomenal progress in paediatric cardiac surgery since the second half of 
the 20th century, starting with the introduction of the Blalock-Taussig-
Thomas shunt in the 1940s and cardiopulmonary bypass in the 1950s, has set 
the stage for successive life-extending intervention and transformed the 
outlook for these children.  
 Overall survival to age 16 of children with congenital heart disease 
now exceeds 90%, and there are now more adults than children with 
repaired congenital heart disease; the proportion of adults being as high as 
66% as life expectancy continues to rise, as shown in Figure 1.1 (Marelli et 
al., 2014, Khairy et al., 2010). As operative mortality in paediatric cardiac 
surgery continues to fall to as low as 2.9% in the most recent published UK 
data (Brown et al., 2015), this will only increase. Care for these patients 
represents, and will continue to represent, an increasing challenge for 
modern healthcare services. 
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Figure 1-1 Changing mortality in congenital heart disease in a regional cohort of 
patients from Quebec, Canada. Figure from (Khairy et al., 2010)1 
 
Histogram bars demonstrate the proportion of deaths (x-axis) for the 
corresponding age group(y-axis) in the period 1987-88 compared to 2004-05. 
The graph (dotted line) shows the proportion of deaths for the general 
population in Quebec for the relevant period.  
                                                            
1 Reprinted with permission from the copyright holder (Elsevier) via Rightslink®, licence number 
4087780156297 
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1.2 Definition and classification 
 
Broadly speaking, an adult with congenital heart disease is an individual 
over the age of 16 years with any form of congenital heart defect, either 
repaired or unrepaired. Congenital heart defects can be classified in 
different ways. They can be divided according to the different structures 
affected, such as those outlined in the International Classification of Disease 
version 9 (ICD-9) codes, although this results in a somewhat daunting array 
of different diagnoses, some of which are specified below (Table 1.1): 
 
 
Table 1-1 ICD 9 codes for congenital heart disease 
Code Descriptor 
745.0 Common truncus 
745.10 Complete transposition of the great vessels 
745.11 Double outlet right ventricle 
745.12 Corrected transposition of the great vessels 
745.19 Other transposition of the great vessels 
745.2 Tetralogy of Fallot 
745.3 Common ventricle 
745.4 Ventricular Septal Defect 
745.5 Ostium secundum type Atrial Septal Defect 
745.60 Endocardial cushion defect unspecified type 
745.61 Ostium primum defect 
745.69 Other endocardial cushion defect 
745.9 Other unspecified defect of septal closure 
746.00 Congenital pulmonary valve anomaly unspecified 
746.01 Atresia of pulmonary valve congenital 
746.02 Stenosis of pulmonary valve congenital 
746.09 Other congenital anomalies of pulmonary valve 
746.1 Tricuspid stenosis and atresia congenital 
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746.2 Ebstein anomaly 
746.3 Congenital stenosis of aortic valve 
746.4 Congenital insufficiency of aortic valve 
746.5 Congenital mitral stenosis 
746.6 Congenital mitral insufficiency 
746.7 Hypoplastic left heart syndrome 
746.81 Subaortic stenosis congenital 
746.82 Cor triatriatum 
746.83 Infundibular pulmonary stenosis congenital 
746.84 Congenital obstructive anomalies of the heart not elsewhere 
specified 
746.89 Other specified congenital anomalies of heart 
746.9 Unspecified congenital anomaly of heart 
747.0 Patent ductus arteriosus 
747.10 Coarctation of the aorta 
747.11 Interruption of the aortic arch 
747.41 Total anomalous pulmonary venous connection 
747.42 Partial anomalous pulmonary venous connection 
747.89 Other specified congenital anomalies of circulatory system 
747.90 Unspecified congenital anomaly of circulatory system 
 
It is immediately obvious that confusion may arise in the case of certain 
examples (e.g. 745.60 and 745.69), and there is a danger that the non-
specialist may not classify lesions in sufficient detail, perhaps opting for 
746.9 when a more detailed review of the information might allow a patient 
to be classified with greater accuracy. The system is further complicated by 
the fact that different ICD classifications are used over different time 
periods, for example ICD-10 replaced ICD-9 in 2008, and is itself due to be 
replaced by ICD-11 in 2017. And finally the ICD system refers only to the 
initial diagnosis and not any subsequent surgical correction of anatomy. So, 
for example, there is no ICD code for patients with a Fontan circulation. A 
separate system, the OPCS (Office of Population Censuses and Surveys) 
22 
 
classification of interventions and procedures, is required to code 
operations. This is subject to similar limitations and complicates 
classification still further. 
 In an effort to expand upon this, and based on earlier work from the 1996 
Canadian Consensus Conference on ACHD, the 2001 Bethesda conference 
divided all defects into defects of simple, moderate and great complexity 
(Warnes et al., 2001). The main drive to classify defects in this way was to 
outline the extent to which ACHD patients require review by subspecialist 
ACHD centres, i.e. none, periodic and regular follow-up for the simple, 
moderate and great complexity defects respectively. The classification is 
not perfect as some lesions such as Ebstein anomaly exhibit a wide spectrum 
of severity in their own right, and a degree of overlap exists between a 
number of the other specified lesions. However, it serves as a useful 
framework for reference, is conceptually easy to understand, and is 
pragmatic. 
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Table 1-2 Bethesda classification of congenital cardiac lesions 
Complexity Diagnoses 
Simple Native Isolated congenital aortic valve disease 
Isolated congenital mitral valve disease 
Isolated PFO or small ASD 
Isolated small VSD 
Mild pulmonary stenosis 
 
Repaired Previously ligated or occluded PDA 
Repaired secundum or sinus venosus ASD 
without residual defect 
Repaired VSD without residual defect 
Moderate Aorto-left ventricular fistula 
Anomalous pulmonary venous drainage (partial or total) 
Atrio-ventricular canal defects (partial or total) 
Coarctation of the aorta 
Ebstein anomaly 
Ventricular Outflow Tract obstruction of significance 
PDA (not closed) 
Pulmonary regurgitation (moderate or severe) 
Pulmonary stenosis (moderate or severe) 
Sinus of Valsalva fistula or aneurysm 
Sinus venosus ASD 
Subvalvar or supravalvar aortic stenosis 
Tetralogy of Fallot 
VSD complicated by: 
 Absent valve 
 Aortic regurgitation 
 Coarctation of the aorta 
 Mitral valve disease 
 Right ventricular outflow tract obstruction 
 Straddling tricuspid/mitral valve 
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 Subaortic stenosis 
 
Great Presence of a surgical conduit (valved or non-valved) 
Cyanotic congenital heart disease (all forms) 
Double outlet ventricle 
Eisenmenger syndrome 
Fontan procedure 
Mitral atresia 
Single ventricle 
Pulmonary atresia 
Pulmonary vascular obstructive disease 
Transposition of the Great Arteries 
Tricuspid atresia 
Truncus arteriosus (including hemitruncus) 
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1.3 Investigation and follow-up of patients with ACHD 
 
The vast majority of patients with ACHD require regular assessment and 
follow-up, it is only in rare instances that a patient can be regarded as 
"cured" , for example a small haemodynamically insignificant VSD that 
resolves spontaneously. As described above any patient with a congenital 
defect of moderate or great complexity requires at least some input from a 
specialist ACHD centre with access to the full range of complex imaging and 
cardiac catheterisation. Clinical assessment is based on the following 
modalities: 
 
1.3.1 Clinical examination 
Documentation of parameters such as heart rate, non-invasive systemic 
arterial blood pressure, and pulse oximetry. A full cardiovascular and 
respiratory examination will assess for the presence of scars, cardiac 
devices, elevated jugular venous pulse, parasternal heave, murmurs or 
bruits, oedema, and pleural fluid, all of which can indicate the presence of 
underlying haemodynamically significant lesions or heart failure. 
 
1.3.2 Electrocardiography 
The 12-lead surface ECG (Figure 1.2) is a straightforward and widely 
available tool that provides a wealth of information regarding electrical 
conduction through the heart. The ECG is rarely normal in congenital heart 
disease, and will often reflect the underlying structural lesion or lesions, for 
example for patients with a systemic right ventricle there will be evidence 
of right axis deviation and right ventricular hypertrophy, and for patients 
with a dilated right ventricle right bundle branch block is frequently 
present. The presence of an atrial or ventricular arrhythmia is clearly of 
immediate relevance in an emergency situation. Furthermore, some 
parameters are of longer term prognostic significance e.g. the duration of 
the QRS complex in repaired Tetralogy of Fallot (Gatzoulis et al., 2000). 
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Figure 1-2 Twelve lead ECG showing sinus rhythm with first degree heart block and 
marked right bundle branch block in a patient with surgically repaired Tetralogy of 
Fallot 
 
 
1.3.3 Echocardiography 
This technique employs a piezoelectric crystal to generate an ultrasonic 
beam which is reflected by the heart and related structures, the analysis of 
which allows real-time two- and three-dimensional digital reconstructions of 
structures as they move throughout the cardiac cycle together with analysis 
of the flow of blood through the heart, and by extension the function of 
valves and conduits (Figure 1.3). Transthoracic probes are most commonly 
used as they are non-invasive, widely available and cheap to use, although 
transoesphageal probes provide better visualisation of more posterior 
structures, and specialist intracardiac and epicardial echo can be invaluable 
to guide percutaneous and cardiac surgical intervention respectively. The 
main disadvantage of echocardiography in congenital heart disease is that 
the highly variable anatomy found in more complex conditions does not lend 
itself easily to interpretation in conventional echo views, the presence of 
scar tissue resulting from prior cardiac surgery degrades image quality, and 
some structures may not be possible to visualise at all. Furthermore, data 
regarding reference ranges for normal values is often lacking, limiting the 
utility of quantitative data obtained. Whilst some conditions have been 
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studied with respect to the prognostic value of certain parameters - for 
example tricuspid annular plane systolic excursion, atrial dilatation, and the 
ratio of right ventricular systolic to diastolic duration and the prediction of 
mortality in Eisenmenger syndrome (Moceri et al., 2012) - most have not.     
 
 
Figure 1-3 Apical four chamber view in a patient with a secundum atrial septal 
defect (arrowed) 
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1.3.4 Plain film chest radiography 
Often underrated, this provides a quick, cheap, and readily reproducible 
image of the heart, mediastinum and lung (Figure 1.4). A normal chest 
radiograph in adulthood is reassuring, and often suggests that an underlying 
structural lesion is unlikely to be haemodynamically significant (Steiner et 
al., 1995, Dimopoulos et al., 2013). In the acute setting it allows rapid 
recognition of  pathology such as pulmonary oedema. And finally, subtle 
changes in the cardiac outline over time can hint at more slowly progressive 
pathology and guide further investigation. 
 
Figure 1-4 Chest X-ray in a patient with unrepaired aortic coarctation, 
demonstrating inferior rib notching (asterisks) 
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1.3.5 Cardiopulmonary exercise testing 
An established incremental increase in workload, generally by treadmill or 
cycle ergometer, allows the measurement of the maximum oxygen uptake 
during exercise and thus quantification of the subject's aerobic exercise 
capacity. Serial changes in the VO2 over time can establish functional 
decline before the development of symptoms, furthermore more detailed 
analysis of response to exercise allows the determination of whether the 
main limiting factor to exercise occurs on the cardiovascular, respiratory or 
gas exchange axes (Figure 1.5).  
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Figure 1-5 Nine-panel plot from CPET performed by a patient post pulmonary valve 
replacement2 
 
 
                                                            
2 From left to right the panels show: top row - minute ventilation against time, oxygen 
pulse (blue) and heart rate (purple) against time, oxygen uptake and carbon dioxide output 
against time; middle row - minute ventilation against carbon dioxide output (the VE/VCO2 
ratio), heart rate (orange) and carbon dioxide output (blue) against oxygen uptake, 
ventilatory equivalents (VE/VO2 and VE/VCO2 ratios against time); bottom row - tidal 
volume (green) and respiratory rate (blue) against time, respiratory exchange ratio (ratio of 
oxygen uptake to carbon dioxide output) against time, and the end tidal oxygen and carbon 
dioxide partial pressures against time. Where time is the x-axis this is colour-coded as 
green: warm-up, red: exercise, and yellow: cool-down.  
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Reference ranges for peak VO2 have been established for one large cohort 
of ACHD patients (Kempny et al., 2012), and it can be helpful to review the 
range of exercise capacity seen amongst patients with the same diagnosis, 
and then compare this to the ranges described for other congenital cardiac 
diagnoses. For example, patients who have undergone the arterial switch 
operation for transposition of the great arteries have a mean peak VO2 of 
89% of the predicted value, whereas for patients with Eisenmenger 
physiology the corresponding value was 43%. Furthermore, a number of 
parameters derived from CPET carry prognostic weight. These include peak 
VO2, the ratio of minute ventilation to carbon dioxide output, heart rate 
response to exercise and chronotropic incompetence, and the oxygen 
uptake efficiency slope (Diller et al., 2005, Dimopoulos et al., 2006, Diller 
et al., 2009, Giardini et al., 2009b).   
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1.3.6 Cardiac magnetic resonance imaging 
This is regarded as the gold standard technique for imaging of the heart in 
the setting of repaired congenital heart disease. Many atomic nuclei, for 
example Hydrogen-1 and Carbon-13 - both widely present in the human body 
- exhibit a property known as 'spin', where application of a strong external 
magnetic field causes the nuclei to align in the same axis. Application of a 
radiofrequency pulse to the nuclei causes them to change their alignment, 
the degree of change is known as the flip angle. Analysis of the signals 
emitted from each nucleus following repeated applications of external 
radiofrequency energy and using different external gradients of magnetic 
fields in three dimensions allows the digital reconstruction of each nucleus' 
position inside a virtual space known as k-space. This information can be 
processed digitally to create a cross-sectional image of the heart in any 
conceivable plane (Figure 1.6). Discrimination of different tissue types due 
to different water content in the case of Hydrogen-1 is highly accurate and 
reproducible. For the heart a series of images throughout the whole cardiac 
cycle can be obtained by acquiring images at different times, gated to the 
vector cardiogram or VCG. Further information can be gleaned from the use 
of Gadolinium contrast, time of flight three-dimensional MRI angiography, 
and T1, T2 and T2 star mapping. The disadvantages of the technique in 
congenital heart disease arise if MRI is contraindicated for example due to 
the presence of a non-MRI conditional cardiac device (although more recent 
research has suggested that some of these device may be safe for scanning 
at 1.5 Tesla), the presence of metallic artefact due to implanted material 
such as prosthetic valve replacements, the long time required to acquire 
and then analyse the images obtained, problems with claustrophobia and 
poor patient tolerance, and the difficulty of assessing the heart in the 
setting of an irregular heart rhythm. As will be seen in the forthcoming 
chapters, in certain situations the quantitative data derived from MRI 
carries prognostic significance and can be invaluable to clinical decision 
making. Most of the evidence applies to adults with repaired tetralogy of 
Fallot, simply by virtue of the fact that this is the commonest form of 
congenital heart disease. Accurate estimation of RV end diastolic volume 
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can help to determine the timing of pulmonary valve replacement (Therrien 
et al., 2005, Oosterhof et al., 2007), and the presence of late gadolinium 
enhancement (Babu-Narayan et al., 2006, Wald et al., 2009) or left 
ventricular dysfunction (Geva et al., 2004) can help to identify patients at 
risk of adverse outcomes. Fewer published data relate to other conditions 
such as atrial septal defect, transposition of the great arteries and single 
ventricle physiology, however the insights each scan can provide in helping  
to understand the precise anatomy and physiology of a patient's heart carry 
great merit on a case-by-case-basis.     
 
Figure 1-6 Steady state free precession sequence in horizontal long axis (four 
chamber view) in a patient with Eisenmenger physiology. Note the right ventricular 
hypertrophy (asterisk) 
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1.3.7 Cardiac catheterisation 
Fluoroscopic imaging of the heart and great vessels with the use of X-ray 
contrast provides invaluable information to assess for the presence of 
abnormal flow of blood from one structure to another or guide subsequent 
percutaneous intervention e.g. device closure of an ASD or balloon 
angioplasty. Direct measurements of pressure and the withdrawal of blood 
samples for analysis of oxygen saturation allows assessment of 
haemodynamic severity of obstructive lesions or shunts, as well as the 
calculation of cardiac output and pulmonary vascular resistance. Invasive 
electrophysiological studies can also be performed, allowing the 
identification of abnormal pathways and re-entry, three-dimensional voltage 
mapping of complex arrhythmias, and ventricular stimulation studies to 
provide information regarding the inducibility of ventricular tachycardia in 
highly selected patient subgroups to help guide the choice of candidates for 
primary preventative ICD therapy.   
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1.4 Treatment 
 
The mainstay of treatment for congenital heart disease involves correction 
of the underlying haemodynamic lesion or lesions. Thus, as mechanical 
problems require mechanical solutions, in practice this means invasive 
intervention. This may be performed through cardiac catheterisation or 
open cardiac surgery, but in some cases a hybrid approach may be used. 
Invasive treatment for moderate or great complexity lesions typically 
involves one or more procedures in early life, following which patients will 
eventually require further intervention to address any residual and 
progressive haemodynamic lesions, generally in early adulthood and beyond. 
Patients with simple congenital cardiac lesions may not undergo any 
intervention in their early life, but particularly in cases where they may 
have been undetected in childhood (for example a secundum atrial septal 
defect, which may cause no symptoms and have only very subtle signs to 
find on examination in early life), they may go on to exert a progressive 
effect on cardiac function over time and threaten to cause life-limiting 
sequelae such as arrhythmia, heart failure or pulmonary arterial 
hypertension, thus leading to a need for intervention which may not be until 
the fourth or fifth decade of life and beyond. 
Medical or pharmacologic therapy has a limited application in ACHD, and is 
essentially pragmatic, for example the use of diuretics in heart failure or 
beta blockers in tachyarrhythmias. Unlike other cardiac conditions such as 
coronary artery disease there are no treatments proven to slow the 
progression of underlying pathology or modify the risk of late complications, 
and patients may respond poorly or not at all to prognosis-modifying drugs 
used in the setting of acquired left ventricular systolic dysfunction for 
example Angiotensin Converting Enzyme inhibitors and Mineralocorticoid 
Receptor Antagonists.   
One extremely important aspect of managing ACHD patients includes the 
provision of expert cardiac and obstetric care to female patients throughout 
all stages of conception, including advice on contraception, pre-pregnancy 
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counselling and genetics assessment, pre-natal care including delivery 
planning, and safe and effective post-natal care and follow-up. Another key 
aspects of care to consider is that as the ACHD population ages so patients 
may develop acquired cardiac conditions such as coronary artery disease, 
however their comorbidity (difficult vascular access, abnormal coronary 
anatomy, need for ongoing anticoagulation, etc.) means treatment may not 
be straightforward. Additionally there is increasing recognition of the 
burden of psychological morbidity in ACHD patients, which may manifest 
itself as health anxiety, low mood and other progressively more severe 
mental health disorders such as severe depression.  
And finally, there is the problem of the extensive socioeconomic effects of 
these conditions. Extensive time spent in hospital limits educational 
attainment and can also lead to problems successfully applying for and 
holding down employment. Many congenital cardiac defects lead to outright 
exclusion from applying for professions such as the armed forces, and the 
sequelae of congenital heart disease can lead to a ban from even more 
professions (e.g. a patient with ACHD who holds a category 1 driving licence 
in the United Kingdom will automatically lose this if they subsequently 
undergo implantation of an ICD). The uncertainty regarding survival and 
long-term prognosis in ACHD patients may result in an inability to gain life 
insurance and loans. "Treatment" of all of these issues is arguably as 
important as the surgical and medical management of ACHD patients. 
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1.5 Prognosis in ACHD 
 
1.5.1 Survival 
As described above, advances in paediatric care have transformed the 
outlook for patients with congenital heart disease. Survival since the 1970s 
has consistently improved for patients with congenital heart disease 
regardless of severity, with a large study of almost 7500 patients from 
Belgium demonstrating that survival from birth to adulthood has increased 
from 81% for patients born in 1970-1974, to 88.6% for those patients born in 
1990-1992. Most of the mortality arises from patients with forms of 
univentricular heart, particularly hypoplastic left heart syndrome. Survival 
to adulthood for the patients with simple or moderate complexity lesions in 
the 1990-1992 birth cohort was as high as 98% and 90% respectively(Moons et 
al., 2010). A decrease in early mortality has been further corroborated by 
data from the USA, Quebec, Norway and the UK (Jortveit et al., 2016, 
Brown et al., 2015, Gilboa et al., 2010, Khairy et al., 2010) 
 
 
1.5.2 Morbidity 
As expected morbidity in this population group is high, but less well 
documented compared to overall survival. Complications include infective 
endocarditis, arrhythmia, heart failure, pulmonary arterial hypertension, 
cardioembolic stroke, and reoperation. The incidence of stroke appears to 
be particularly high, with one study estimating that 1 in 11 of all male 
patients from age 18-65 will experience a stroke (Lanz et al., 2015). 
Furthermore, as patients become older, so they experience the full range of 
conditions associated with the aging process such as ischaemic heart disease 
and malignancy. Another important cause of morbidity is that resulting from 
pregnancy, and indeed in cases where the mother has congenital heart 
disease there is a significantly greater risk of both maternal and fetal 
adverse outcomes (Drenthen et al., 2007) 
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1.5.3 Hospital admissions 
Contemporary data suggests an increase in hospital admissions of adult 
patients with congenital heart disease in England and Wales, the USA and 
the Netherlands, consistent with the increase in size of the ACHD population 
(Billett et al., 2008, Verheugt et al., 2010, Opotowsky et al., 2009). The age 
of patients admitted appears to be increasing, and the commonest reason 
for emergency admission is arrhythmia (Verheugt et al., 2010). All of this 
suggests an increase in healthcare utilisation for this patient group.  
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1.6 Problems in defining prognosis for a contemporary cohort of 
ACHD patients 
 
 As alluded to in the previous section, data regarding prognosis in any 
group of ACHD patients is hampered by a host of different factors. Perhaps 
the most important is that even in a single diagnostic category, e.g. patients 
with repaired Tetralogy of Fallot (TOF), there exist a wide range of baseline 
variables which are difficult to adjust for. First and foremost, the severity 
of the underlying haemodynamic lesions will  differ from patient to patient. 
Patients with milder lesions (a smaller VSD, less overriding of VSD by the 
aorta, less outflow tract obstruction) will thrive more in the first few weeks 
of life so they have a higher weight preoperatively, and they may also 
require a less radical surgical repair which will decrease operative risk and 
reduce the likelihood of needing repeat intervention in the future. On the 
other hand, patients with more severe lesions will have a higher operative 
risk, require more extensive surgery at the time of initial repair, and will be 
more likely to have significant residual haemodynamic lesions which will 
need to be addressed in the future. In the case of repaired TOF a further 
demonstration of this principle can be made by considering the issue of 
where the right ventricular outflow tract obstruction occurs. If this is at the 
level of the infundibulum then the patient may require only an infundibular 
resection, leaving the pulmonary valve intact. On the other hand the 
patient with obstruction at the level of the valve may require a transannular 
patch repair, which destroys the valve. This leaves them with free 
pulmonary regurgitation, and so the need for pulmonary valve replacement 
at a later date is effectively guaranteed.  
As well as the underlying anatomy, it must be remembered that patients 
under follow-up by any centre will have been operated upon at different 
ages and in different eras, and this will also affect prognosis. A patient who 
underwent primary repair of TOF in the late 1990s at a few months of age 
will have a very different outlook to the patient who was operated on as a 
teenager in the 1970s after one or two palliative shunt procedures.  
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Yet another problem is that there is no standardised way for reporting 
survival in these patient groups. Some centres report survival across their 
entire cohort of patients (i.e. as a whole for all patients operated upon from 
as early as the late 1950s to the current era), whereas others present 
survival according to groups who underwent surgery within specified 
chronological periods, however with this approach there is no consensus on 
how long these intervals should be. Another point of interest is that of 
differences in operative mortality between different surgical centres and 
individual surgeons, which will impact upon long term results if included in a 
survival analysis. In some places this variation is likely to be negligible - for 
example in the UK the publication of the Bristol Inquiry in 2001 (Kennedy, 
2001) resulted in congenital cardiac centres and surgeons in the UK 
becoming subject to national audit and perhaps the heaviest scrutiny 
amongst any medical specialty, thus ensuring the upholding of accepted 
standards in surgical outcomes. However this does not always apply 
internationally, or indeed historically.  
Another key issue is the lack of follow-up into adulthood. Some centres 
worldwide, of which Scotland is now one, can offer a centralised congenital 
cardiology service which follows up patients from infancy all the way 
through to adult life and beyond. However this is not universal. In other 
places children may attend the congenital cardiac centre for their initial 
corrective surgery, but may be followed up at a different institution. Whilst 
it is usually straightforward to find out whether these patients are at least 
still alive in the longer term, this is not always the case. Furthermore,  
survival is often the only parameter which can be easily assessed, and it can 
prove very difficult to get even basic information on functional status and 
the results of various cardiac investigations performed at follow-up. There is 
a particular dearth of information regarding the results of advanced 
investigations such as CPET and cardiac MRI in the published literature.   
The final issue relates to the problem of assessing prognosis for the 
exclusively adult patients with congenital heart disease. The prognosis for a 
16 year old with a univentricular heart who has undergone a Fontan repair 
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will not be the same as a neonate with unrepaired univentricular heart. In 
many ways the patients who have survived to their adult years represent an 
"elite" group of survivors who have survived the peak of early mortality, and 
quoting overall survival statistics for them from birth is of limited 
relevance: there may well be 70% survival to age 30 for their birth cohort, 
but as they have already survived to age 16 their chances of reaching age 30 
will be proportionately higher. This leads to the problem of deciding upon a 
suitable baseline for performing survival analysis, and furthermore one must 
also find a way of accounting for "left-censoring", i.e. the patients who have 
already experienced the outcome of interest before the baseline of 16 
years.   
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1.7 The situation in Scotland 
 
Scotland is uniquely placed to answer questions relating to long term 
prognosis for adult survivors of congenital heart disease. In the early 2000s 
all paediatric cardiac surgery and percutaneous intervention moved to a 
single centre based at the Royal Hospital for Sick Children in Glasgow, and 
in fact even before this the vast majority of this workload was performed in 
Glasgow. Then in 2006 the provision of adult cardiology care for patients 
with congenital heart disease was reformed with the creation of the Scottish 
Adult Congenital Cardiac Service (SACCS), and this was fully established and 
functional by 2009, based at the Golden Jubilee National Hospital in 
Clydebank, just to the west of Glasgow. This employed the "hub-and-spoke" 
model widely accepted to be the gold standard in management of patients 
with moderate or great complexity congenital heart disease, and was the 
only tertiary centre in country which could offer the full range of congenital 
cardiac services to ACHD patients. Patients with the most complex forms of 
ACHD would undergo almost all of their cardiac care at the single national  
centre, and patients with moderate complexity ACHD would undergo 
periodic review at the national centre, with all of their advanced 
investigations such as cardiac MRI and cardiopulmonary exercise testing, and 
all of their cardiac surgical or percutaneous intervention performed in this 
single location. This means that all ACHD patients with moderate or great 
complexity lesions are under regular follow-up by this single centre, and 
collection of data on outcomes has been assisted by the creation of a locally 
held database. 
Through nationalised data collection on hospital admissions performed by 
the Information and Statistics Division of NHS Scotland information on rates 
of hospitalisation and comorbidity can be corroborated, although there 
remain the problems of coding for complex congenital cardiac diagnoses, 
and the results of clinical parameters derived from various cardiac 
investigations will not be documented (so, for example, one could not use 
the ISD dataset to assess whether the QRS complex duration on an ECG is 
associated with adverse clinical outcomes). If this can be overcome then 
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this could also provide a unique and valuable resource for studying this 
population group - especially with regards to hospital admissions and 
outcomes extending back before 2009, and the establishment of SACCS and 
the locally held database.   
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1.8 How might our understanding of the prognosis for patients 
with ACHD be improved using the Scottish data? 
 
The most comprehensive and robust data on clinical outcomes for ACHD 
patients in Scotland exists for patients with moderate and great complexity 
congenital cardiac lesions as by virtue of their underlying diagnosis all such 
patients must pass through the national congenital cardiac centre, both for 
periodic review and also for any form of intervention. For patients with 
"simple" congenital defects the situation is complicated by the fact that the 
bulk of their follow-up will be at a non-specialist or local centre, and so 
there will be a large number of patients missing from our database who 
have never presented to the national centre. 
At the same time it is important to ensure that the diagnostic groups 
assessed are relatively homogenous. So for example it would be difficult to 
study patients with an ASD, as although they account for a large population 
they differ greatly in their presentation. Some patients may present to the 
attention of cardiac services only during middle age when they develop 
problems such as atrial arrhythmia (having been asymptomatic beforehand), 
some patients with a small ASD may never present to secondary care, and 
there is also the problem of adjusting for the type and timing of 
intervention, e.g. whether or not and at what age the patient has 
undergone open surgical repair or device closure of an ASD.  
The best groups of patients to study will be those who are easily classified 
into a particular diagnostic group, who have conditions of sufficient 
complexity they will all be followed up at the national centre with advanced 
cardiac investigations such as cardiac MRI, and who form a large enough 
group that their management and outcomes will be of relevance to 
clinicians involved in the care of ACHD patients. Two groups that appear to 
meet this criteria are those patients with a systemic right ventricle, either 
as a result of congenitally corrected transposition of the great arteries 
(CCTGA) or atrial inversion surgery for transposition of the great arteries 
(TGA), and patients with repaired TOF.  
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1.9 Aims of the thesis 
 
This thesis aims to address the issue of defining long term outcomes and 
prognosis for Scottish adults with congenital heart disease by addressing the 
following five questions: 
1. What is already known about the long term prognosis for adult 
patients with a systemic right ventricle? 
2. What is already known about the long term prognosis for adult 
patients with repaired Tetralogy of Fallot? 
3. What does the Scottish data tell us about long term outcomes for long 
term adult patients with a systemic right ventricle in comparison to 
other centres? 
4. What does the Scottish data tell us about long term outcomes for long 
term adult patients with repaired Tetralogy of Fallot in comparison to 
other centres? 
5. Can data from cardiac MRI and cardiopulmonary exercise testing help 
to identify the reasons for any differences in outcomes?   
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Chapter 2 Methods 
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2.1 Preamble 
 
This chapter outlines the methodology common to all subsequent chapters 
of this thesis. Where more specialised techniques were used, a more 
detailed explanation follows in the relevant chapter. 
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2.2 Patient selection 
 
Since 2009 all care for adult patients with congenital heart defects of 
moderate or greater complexity in Scotland has been centralised. Care is 
provided by the Scottish Adult Congenital Cardiac service which is based at 
the Golden Jubilee National Hospital in Clydebank. All patients in the 
greater Glasgow area are followed up at this location on a regular basis; 
patients who are more geographically remote may undergo routine follow-
up up at a secondary care  centre closer to their place of residence, 
however they would still attend the national centre every 2-3 years for a 
more comprehensive clinical review which would normally include the use 
of advanced imaging and investigation. Furthermore all congenital cardiac 
surgery and percutaneous procedures are performed at the national centre. 
All patients were registered in a clinical database and coded according to 
diagnosis. All patients with following diagnoses were eligible for inclusion: 
 Systemic right ventricle:  
o Congenitally corrected transposition of the great arteries 
(CCTGA) 
o Transposition of the great arteries status post atrial switch 
operation - either a Mustard or Senning operation (TGA atrial 
switch) 
 Tetralogy of Fallot (TOF) post surgical repair 
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2.3 Ethical approval 
 
This was a purely descriptive study assessing long term outcomes in 
congenital heart disease in the Scottish population compared to outcomes in 
other populations of congenital heart disease patients. Advice from the 
West of Scotland Research Ethics Service was sought regarding the need for 
Research Ethics Committee approval. As the project involved the use of 
previously collected routine clinical data and compared outcomes in our 
cohort to those of other centres it was felt to be more in keeping with 
audit, and so this requirement was waived (see Appendix). At the time of 
initial data collection in 2011 there was no process to register the study 
locally as an audit with the Golden Jubilee National Hospital, however when 
it became apparent that further data was required for the TOF cohort in 
2015 this had changed, and so the project was formally registered as such 
(local registration number 1518).  
 To guarantee patient confidentiality and anonymity all patient 
identifiable data were stored on an encrypted, password protected NHS 
drive at the Golden Jubilee National Hospital. Initial data were entered into 
a Microsoft Excel spreadsheet, each patient was assigned an computer 
generated random identification number, and then any unique personal 
identifiable data (e.g. name, date of birth, postcode) was removed prior to 
converting the spreadsheet into an SPSS Statistics Data Document file to 
allow statistical analysis of the resultant fully anonymised data. Caldicott 
guardian approval was discussed and agreed before each round of data 
collection; in 2011 and 2015. 
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2.4 Data collection 
 
All patients were tracked through the SACCS central database which 
contains a summary of their basic anatomy, previous interventions and 
current diagnoses as well as links to the most recent clinic letters and 
results of investigations. Clinic letters included data regarding current NYHA 
status and medication. If clarification was required, these records could be 
corroborated with information held in the national Scottish Care Information 
(SCI) Store or by an application to the National Records of Scotland (NRS), 
which succeeded the General Register Office for Scotland in 2011. If there 
was no original operation note on the database for a patient who underwent 
their original surgery in the west of Scotland we also attempted to trace the 
hard copy of the operation note which was held in an archive at the Royal 
Hospital for Sick Children at Yorkhill in Glasgow. 
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2.5 Clinical investigations 
 
2.5.1 Electrocardiogram 
Standard surface 12 lead ECGs (stored electronically) were performed and 
analysed for the following parameters 
 Heart rate: expressed as beats per minute or bpm and calculated 
from the R-R interval (the time between each preceding R wave in 
milliseconds) according to the following formula: HR = 60000 / R-R. 
Where the R-R interval was irregular this could be averaged over a 
duration of 10 seconds. 
 Heart rhythm: this was analysed manually and categorised into sinus 
rhythm, paced rhythm, atrial fibrillation, atrioventricular block (first, 
second or third degree), or bigeminy. 
 QRS interval: this was defined as the duration in milliseconds 
between the point of initial deflection from the baseline (either a 
positive R wave or negative Q wave) and the point at which the 
terminal deflection of the S wave crossed the baseline. This was 
analysed in the lead with the most obvious and widest complex. 
 
2.5.2 Transthoracic echocardiography 
Standard two-dimensional cardiac ultrasound was performed in patients at a 
variety of centres and with different equipment, furthermore its limitations 
in the assessment of patients with congenital heart disease are well 
recognised - specifically reduced image quality secondary to scarring from 
previous surgery, the difficulty in imaging a complex three-dimensional 
structure such as an abnormal right ventricle by purely two-dimensional 
means, the lack of consensus on the best variables by which to assess the 
severity of a particular abnormality, and the consequent difficulty in 
obtaining precise and reproducible measurements. The decision therefore 
was made to utilise the semiquantitative reports to characterise cardiac 
chambers and valves. All sonographers at the Golden Jubilee National 
Hospital are accredited nationally with the British Society for 
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Echocardiography, thus providing adequate quality assurance. The 
qualitative measurements recorded were: 
 Right and left ventricles:  
o Chamber size: mild, moderate, severe dilatation 
o Systolic function: mild, moderate, severely systolic dysfunction 
 Valve function: 
o Documented for the four valves: pulmonary, aortic, tricuspid 
and mitral 
o Categorised as normal, replaced, regurgitant (trivial, mild, 
moderate or severe), or stenosed (mild, moderate or severe) 
o In the case of a replaced valve if the residual stenosis or 
regurgitation was present and felt to be moderate or greater 
this was characterised as "replaced - stenosed" or "replaced - 
regurgitant" 
 Residual ventricular septal defect: presence or absence 
 
2.5.3 Cardiopulmonary exercise testing 
All cardiopulmonary exercise testing was performed using a bicycle 
ergometer (Medisoft, Sorinnes, Belgium). All patients followed a standard 
protocol of a 2 minute rest period, 3 minutes of unloaded exercise, and then  
the commencement of incremental workload of 10-20 watts per minute. A 
fixed cadence of 60 rotations per minute was used. Tests were performed in 
accordance with standards as defined by the European Society of Cardiology 
(Mezzani et al., 2009). Variables measured were:  
 Height and weight 
 Heart rate 
 Surface ECG 
 Noninvasive blood pressure measurement 
 Capillary oxygen saturation or SpO2 
 Minute ventilation 
 Concentration of inspired and expired oxygen and carbon dioxide 
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From this data the following variables could be calculated: 
 
 Peak oxygen uptake VO2, which could be expressed as an absolute 
value in L/min, a value indexed to body surface area as ml/kg/min, 
or as a percentage of the predicted value in healthy individuals 
matched for age, gender and height (Jones et al., 1985)  
 The VE/VCO2 slope. This is the ratio between minute ventilation and 
carbon dioxide output during exercise, and is calculated by linear 
regression from the start of the exercise test to the VCO2 at 
anaerobic threshold. This parameter is dimensionless, and a value of 
less than 30 is considered to be normal. It is a marker of ventilatory 
efficiency which has previously been shown to be more strongly 
predictive of mortality and adverse outcomes in patients with 
repaired congenital heart disease (Dimopoulos et al., 2006).  
 Heart rate reserve (HRR), which was expressed as the difference 
between the maximum heart rate at peak exercise and the predicted 
maximum heart rate at peak exercise. The predicted maximum heart 
rate at peak exercise was calculated according to the formula 220 - 
age in years (Tanaka et al., 2001). This has also been shown to be of 
prognostic value in adult congenital heart disease (Diller et al., 
2006).  
 
2.5.4 Cardiac MRI 
All cardiac MRI scans were performed at the Golden Jubilee National 
Hospital. Images were acquired at a field strength of 1.5 Tesla with a 
Siemens Magnetom Avanto (Siemens AG, Erlangen, Germany) utilising a 12 
element phased array surface coil designed for cardiac imaging. Continuous 
ECG monitoring was employed for every case and full resuscitation facilities 
were available.  Figure 2.1 outlines the imaging protocol used. Steps 1-4 
were performed in every case; where the administration of Gadolinium was 
indicated steps 5 was performed as well. The decision to administer 
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Gadolinium was a purely clinical one and was made by the consultant (HW) 
responsible for the congenital cardiac MRI scans at our institution, generally 
any patient with a congenital cardiac condition characterised by a risk of 
sudden cardiac death (i.e. including those patients with a systemic RV and 
repaired TOF) and no contraindication to the administration of Gadolinium 
would have this administered as part of their index scan at our institution, 
although this was not generally repeated for subsequent scans. 
 
  
 Figure 2-1 Cardiac MRI protocol
 
Once the patient was ready for scanning initial localiser sequences were 
obtained followed by HASTE 
Echo) sequences. These characterised gross cardiac anatomy specifically 
visceral and cardiac situs, atrioventricular and ventriculo
connections, and the relationships of the great vessels as well as
abnormality of cardiac chamber size. Typical settings were as follows: voxel 
size 2.3 x 1.3 x 6.0mm with repetition time (TR) 700ms, echo time (TE) 
43ms, flip angle 160 degrees, and slice thickness 6.0mm.
The next step in the protocol included s
images in the following long axis planes: vertical long axis (LV 2 chamber), 
1
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• HASTE sequences
3
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• Velocity encoded flow maps
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• Navigator non
• Administration of Gadolinium contrast
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• Late Gadolinium Enhancement
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horizontal long axis (LV 4 chamber), LV outflow tract (LV 3 chamber), aortic 
arch, RV outflow tract (in two orthogonal planes), RV 2 chamber, and RV 
inflow-outflow (RV 3 chamber views). A short axis stack of 10mm slices 
through the left and right ventricles from base to apex was also obtained. 
Typical settings were: voxel size 1.5 x 1.3 x 6.0mm with TR 48.79ms, TE 
1.21ms, flip angle 80 degrees. To assess function of the aortic and 
pulmonary valves phase-contrast velocity encoded flow mapping was 
performed in through-plane short axis views during breath holding, with an 
appropriate velocity envelope selected (generally 100 cm/s for a low 
velocity regurgitant jet). Settings for these sequences were voxel size 1.3 x 
1.3 x 5.0mm, TR 29.90ms, TE 2.18ms, flip angle 30 degrees.  
Once this was performed a non-contrast magnetic resonance angiogram was 
obtained. This prospectively gated sequence uses a free breathing navigator 
at the apex of the right hemidiaphragm together with ECG monitoring to 
allow the acquisition of data over a large field of view in end-expiration and 
end-diastole. Settings were: voxel size 1.5 x 1.4 x 0.8mm, TR 285.54ms, TE 
1.56ms, flip angle 90 degrees.    
The final stage in the scan involved the acquisition of late gadolinium 
enhancement (LGE) images. Single shot SSFP acquisitions were made 10-15 
minutes after the administration of 0.15mmol/kg of Gadolenic acid 
(Dotarem®) through a peripheral intravenous cannula. The entire LV and RV 
were imaged using a phase sensitive inversion recovery (PSIR) sequence in 
contiguous short axis views from the level of the AV valves to the apex, and 
then in long axis views (VLA, HLA, LV 3-chamber, RV outflow tract, and RV 
inflow-outflow). Typical imaging parameters were as follows: voxel size 3.5 
x 1.8 x 8.0mm, TR 23.49ms, TE 1.12ms, flip angle 30 degrees. Inversion time 
was optimised to null normal myocardium. 
Post-procedure analysis was performed using a Siemens Argus workstation. 
Volumetric analysis was calculated from the short axis stack dataset via 
assisted planimetry. Firstly end-diastole and end-systole were defined, and 
the most basal slice designated for both the LV and RV. Endocardial 
contours were traced for both chambers at end-diastole and end-systole in 
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each 10mm short axis slice, and the resultant two-dimensional area was 
used to calculate the corresponding blood pool volume for each 10mm short 
axis. The volumes for each short axis slice were added together to give the 
end diastolic volume (EDV) and end systolic volume (ESV) in ml for both the 
LV and the RV. These values were indexed to body surface area giving the 
LVEDVi, LVESVi, RVEDVi and RVESVi in ml per m2, and allowed the 
calculation of ejection fraction (EF) according to the formula:  
 
𝐸𝐹 =
(𝐸𝑛𝑑 𝐷𝑖𝑎𝑠𝑡𝑜𝑙𝑖𝑐 𝑉𝑜𝑙𝑢𝑚𝑒 ∙ 𝑚𝑙 − 𝐸𝑛𝑑 𝑆𝑦𝑠𝑡𝑜𝑙𝑖𝑐 𝑉𝑜𝑙𝑢𝑚𝑒 ∙ 𝑚𝑙)
𝐸𝑛𝑑 𝐷𝑖𝑎𝑠𝑡𝑜𝑙𝑖𝑐 𝑉𝑜𝑙𝑢𝑚𝑒 ∙ 𝑚𝑙
×  100 
 
The practice at our institution is to exclude papillary muscles from analysis 
of LV volumes, but to incorporate trabeculations into analysis of RV 
volumes. To analyse pulmonary regurgitant fraction the velocity encoded 
sequences were used. The valve orifice was defined with planimetry 
throughout the cardiac cycle, and the forward and reverse flow through the 
valve calculated. This allowed the calculation of the regurgitant fraction 
(RF) according to the expression: 
 
𝑅𝐹 =  
𝑅𝑒𝑔𝑢𝑟𝑔𝑖𝑡𝑎𝑛𝑡 𝑉𝑜𝑙𝑢𝑚𝑒 ∙  𝑚𝑙
𝑆𝑡𝑟𝑜𝑘𝑒 𝑉𝑜𝑙𝑢𝑚𝑒 ∙  𝑚𝑙
 ×  100 
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2.6 Statistical analysis 
 
Data analysis was performed using IBM SPSS Statistics version 22 (IBM 
Corporation, Armonk, New York). Continuous variables were expressed as 
mean and standard deviation for normally distributed data, and median and 
interquartile range for non-normally distributed data. Comparison between 
groups was performed using an independent samples T-test, Mann Whitney U 
test or Chi squared test as appropriate. Assumption of normality or non-
normality was derived from graphical representation by means of a 
histogram, or the Shapiro-Wilk test of normality. A p-value of less than 0.05 
was considered significant. 
Survival analysis is outlined in more detail in chapters 4-6. Briefly, 
cumulative survival was estimated using the life table method, and 
graphically represented using Kaplan Meier curves. Comparisons between 
survival curves were made using the log rank test. Univariate and 
multivariate analyses were performed using the Cox proportional hazards 
model. 
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Chapter 3 Long term morbidity and 
mortality in Tetralogy of Fallot and 
Systemic Right Ventricle: a literature 
review 
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3.1 Introduction 
 
As outlined in chapter 1 the birth prevalence of congenital heart 
disease is increasing (van der Linde et al., 2011), and combined with 
advances in the prenatal diagnosis and surgical management of children 
with congenital heart disease of there has been a dramatic improvement in 
overall survival to adulthood. However, beyond this point, the prognosis for 
adults with congenital heart disease is uncertain. Life expectancy is poorly 
defined, furthermore as outlined in the previous chapter corrective surgery 
is often palliative rather than curative, and this results in extensive 
morbidity. There are a host of recognised long term sequelae following 
surgical repair, some of these may be generic, for example endocarditis and 
arrhythmia, whilst others relate to the specific surgical technique involved, 
for example severe pulmonary regurgitation in the case of transannular 
patch repair of Tetralogy of Fallot. Some of these complications have been 
recognised only recently, e.g. aortic root dilatation in Tetralogy of Fallot 
(Mongeon et al., 2013), raising the possibility of more as yet under-
recognised complications in later adult life. Furthermore, as patients age so 
they are at risk of developing acquired cardiovascular disease, and it is 
unclear whether or not they are at greater risk of this than their 
contemporaries (Tutarel, 2014).  
In this chapter I characterise what is already known about the long 
term mortality and morbidity in the two cohorts of ACHD patients relevant 
to my thesis; those with a systemic right ventricle and those with surgically 
repaired Tetralogy of Fallot. These conditions are rare - birth prevalence 
per 1000 live births has been reported at 0.34 for TOF and 0.31 for TGA (van 
der Linde et al., 2011), and at less than 0.07 for CCTGA (McCombe et al., 
2016), but they are among the more common of the congenital cardiac 
conditions of at least moderate complexity, and for the reasons outlined in 
chapter 1 comprise a well defined population with regular follow-up.  
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3.2 Methods 
 
I undertook a literature search of Ovid MEDLINE and Embase (1980 to 
November 2016 week 3) to identify papers relating to long term prognosis in 
systemic right ventricle and repaired Tetralogy of Fallot. Eligibility criteria 
included: 
1. Must refer to outcomes in: 
a. Transposition of the Great Arteries post atrial switch 
surgery 
b. Congenitally Corrected Transposition of the Great Arteries  
c. Surgically repaired Tetralogy of Fallot 
2. Must provide longitudinal data on mortality and morbidity into 
adulthood, i.e. papers were excluded if they related exclusively to 
outcomes in neonatal or paediatric patients 
3. Include at least 50 patients 
4. English language publication 
 
  Three search queries were run: a subheading search specific to each 
of Medline and Embase, and a textword search run simultaneously for both 
Medline and Embase. Terms used included "congenital heart disease", 
"survival", "mortality", "morbidity", "transposition of the great arteries", 
"congenitally corrected transposition of the great arteries", "systemic right 
ventricle", "D-TGA", "L-TGA", "Mustard", Senning", "atrial inversion", 
"tetralogy", and "Fallot". I screened titles and abstracts, and if an article 
was deemed to be relevant then the full text was reviewed to see if the 
paper met the eligibility criteria outlined above. 
 
 It became apparent in the course of the project that some centres 
published outcomes from the same cohort of patients on more than one 
occasion, and if the dates of follow-up overlapped then there was of course 
the risk of duplicating the same data. In these cases generally the most up 
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to date paper was used, an important exception being if it had fewer years 
of patient follow-up owing to the subject of interest being a specific 
subgroup of that cohort. Additionally in the TGA-atrial switch and CCTGA 
groups care had to be taken that the cohort included patients with a 
systemic right ventricle; therefore papers were excluded if they related 
exclusively to patients undergoing surgical correction of TGA or CCTGA that 
resulted in the left ventricle being placed in the systemic or subaortic 
position. Examples of such procedures include the Arterial Switch (Jatene) 
procedure for TGA, the Rastelli, REV (Réparation a l'Étage Ventriculaire) and 
Nikaidoh procedures for TGA complicated by the presence of a VSD and 
pulmonary stenosis, and combinations of these procedures with an atrial 
switch operation for complex CCTGA - a "double switch" or "anatomical" 
repair. Papers were also excluded if they related to patients with the most 
severe form of TGA and CCTGA who were palliated by means of a 
univentricular repair, with the end result being the formation of a Fontan 
circuit. These patients, even though the right ventricle is in the systemic 
position, have a very different physiology to those patients with a 
functionally biventricular heart, and so outcomes and prognosis are not 
readily comparable to their contemporaries. If a paper related to patients 
with TGA or CCTGA who underwent various types of repair then an attempt 
was made to exclude any data relating to those patients who did not have a 
systemic right ventricle. In the case of TGA this was often straightforward as 
the results were typically presented separately, unfortunately for the 
papers relating to CCTGA data was often presented for the cohort as a 
whole, and therefore was much more difficult to disentangle. In this case I 
made the decision to include these papers and present them as published, 
as in general the number of patients undergoing an anatomic repair or 
Fontan was small, and if I instead excluded these papers outright there 
would have been no papers relating exclusively to adult patients with 
CCTGA whatsoever.  
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 The following data were extracted according to diagnosis: centre 
name, number of cases, anatomical subtype or type of surgical repair, ratio 
of male/female patients, age at surgical repair (where applicable), surgical 
era (earliest and latest year of initial surgery), baseline for the purposes of 
follow-up, mean/median follow-up duration, number of deaths, cumulative 
survival at 1-5 year intervals, incidence of morbidity, and risk factors 
associated with mortality. Centres differed in their reporting of 
perioperative or early postoperative mortality (generally defined as a death 
occurring within 30 days of surgery). Where possible this was highlighted in 
the results tables, furthermore if early mortality was not included in the 
survival analysis the number of patients in the cohort as baseline was 
adjusted to ensure it accurately reflected this.   
 
Morbidity outcomes were lesion specific but where relevant included 
incidence of reoperation, device implantation, arrhythmia, and heart 
failure. Morbidity information was expressed as a percentage of the whole 
cohort, unless follow-up was incomplete and some patients had missing 
data. If this was evident then the denominator was adjusted to reflect the 
number of patients for whom follow-up was available. Risk factors for 
mortality were included if they were statistically significant (defined as p 
less than or equal to 0.05) on a multivariate analysis. 
 
Some papers summarised data regarding more than one congenital 
cardiac diagnosis. Where this occurred the data was stratified according to 
diagnosis. The diagnosis-specific data had to include more than 50 patients, 
relate to adult patients, and also correlate with one of the diagnostic groups 
outlined in the data collection (so data was excluded if for example the 
study reported outcomes for a group of patients with TGA but did not 
distinguish between patients with an atrial or arterial switch).  
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 Data were tabulated; no meta-analysis was attempted as the studies 
were sufficiently heterogeneous that it would not have been possible to 
adjust for crucial underlying differences between each study population. 
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3.3 Results 
 
3.3.1 Data collection 
 
The initial search of Medline and Embase using the three search 
strategies yielded 1444 records  (Figure 1). Following title and abstract 
screening to remove papers which were obviously not relevant, duplicates, 
and non-English publications a total of 88 full text articles were retrieved. 
Of these papers 49 were excluded: 15 overlapped with another paper from 
the same centre, 6 reported outcomes for paediatric patients only, 3 had 
cohort sizes of less than 50 patients, and 20 did not report survival data or 
did not report it in a way that allowed comparison with other studies (for 
example they did not present results according to congenital heart disease 
subtype). This generated 39 papers for detailed review, of which 1 
contained data regarding both TGA-atrial switch and TOF, 1 contained data 
regarding systemic RV and TOF, and 1 contained data regarding TGA-atrial 
switch and CCTGA. This gave a total of 20 articles relating to patients with a 
systemic RV and 21 relating to patients with repaired TOF. 
 
  
Figure 3-1 PRISMA flowchart
 
 
 
 
 
 (Liberati et al., 2009) 
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3.3.2 Systemic right ventricle 
 There were a total of 20 papers which referred to outcomes in 
patients with a congenital cardiac condition characterised by the presence 
of a systemic right ventricle (tables 3.1 - 3.3). Of these 14 referred to 
patients with TGA-atrial switch, 4 referred patients with CCTGA, 1 referred 
to patients with both TGA-atrial switch and CCTGA, and 1 referred to data 
for "systemic right ventricle", with no differentiation of the patients within 
that cohort. Lesion-specific information is outlined as follows: 
 
3.3.2.1 TGA-atrial switch 
Baseline demographics: 
There were a total of 15 papers reporting outcomes in 2898 patients. Where 
patient gender was reported, 23-46% were female. The selected baseline for 
long-term follow-up of these patients was exclusively the time of original 
atrial switch surgery. Median follow-up ranged from 11.7 - 35 years, those 
studies published more recently naturally tended to have the greater period 
of follow-up. Era of surgical repair was generally from the mid 1960s to 
early 1990s, although some centres were still performing atrial switch 
surgery for selected patients as late as the early 2000s (Lange et al., 2006, 
Vejlstrup et al., 2015). Mean / median age of surgical repair was relatively 
consistent at less than 2 years, with the exception of one paper from Zurich, 
which in fact included some of the very first patients to have undergone the 
Senning operation (Turina et al., 1989).  
 
Mortality: 
The estimated cumulative survival varied from 61% at 15 years in an early 
cohort (earliest operation date 1958) to 91% at 20 years in a more recent 
cohort of patients with simple TGA (Morris and Menashe, 1991, Dos et al., 
2005). Sudden death in patients with repaired congenital heart disease is a 
subject of particular interest, and up to 71% of those patients who died, 
died in this way. It is worth noting that the lowest percentage of 7% was 
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reported in a paper which included 62 perioperative deaths (Moons et al., 
2004), thus heavily weighting the analysis in favour of early surgical 
mortality. Papers which did not include early surgical mortality generally 
quoted sudden death as occurring in over 40% of the patients who died 
during the follow-up period.  Multivariable models to identify risk factors for 
mortality were generally the exception rather than the rule, however early 
surgical repair and the presence of associated congenital cardiac lesions 
such as VSD were identified as conferring a worse prognosis from baseline 
(Cuypers et al., 2014, Vejlstrup et al., 2015). 
  
Morbidity 
Up to 39% of patients required surgical reoperation, where the reason for 
this was outlined in the manuscript this was generally for haemodynamic 
problems arising from the interatrial baffles. Arrhythmia occurred in up to 
40% of patients, with the lowest prevalence of 7-8% being reported in the 
earliest studies (Morris and Menashe, 1991, Turina et al., 1989). Most 
arrhythmias were supraventricular, and where ventricular arrhythmia was 
reported this occurred in 6% of patients (Cuypers et al., 2014). Permanent 
pacemaker was required in up to 33% of patients, however the proportion of 
patients with an ICD was not well described. Only two papers documented 
this, and both reported it at 5-6% (Cuypers et al., 2014, Wheeler et al., 
2014). Systemic tricuspid valve repair or replacement occurred in up to only 
2.7% of patients when reported (Sarkar et al., 1999), despite the reported 
prevalence of severe tricuspid regurgitation of up to 38% in one of the most 
recent publications (Cuypers et al., 2014).  
 
Differences between Mustard and Senning cohorts: 
Three papers assessed whether there was a difference in outcomes between 
those patients who underwent a Mustard procedure, and those who 
underwent a Senning repair (Moons et al., 2004, Sarkar et al., 1999, Lange 
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et al., 2006). Two reported worse survival with a Mustard repair (Lange et 
al., 2006, Sarkar et al., 1999), and all reported a higher incidence of baffle 
obstruction and / or reintervention for the Mustard group. However it is 
important to note that this was based on a univariate comparison. In all 
three centres the Senning repair was generally introduced after 1980, with 
the majority of Mustards performed before this date, thus introducing 
surgical era / birth cohort effect as an important confounding factor. 
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3.3.2.2 CCTGA 
Baseline demographics: 
There were five studies reporting outcomes for 609 patients, of which 34-
40% were female. Two studies reported outcomes for all patients with 
CCTGA (Dobson et al., 2013, Rutledge et al., 2002), the remaining three 
reported outcomes only in patients who had undergone some form of 
corrective cardiac surgery (Lim et al., 2010, Hraska et al., 2005, Yeh et al., 
1999). Associated lesions were extremely common, with estimates of VSD 
prevalence ranging from 65-86%, pulmonary stenosis from 37-64%, and 
pulmonary atresia from 15-31% (higher in the three surgical cohort studies).  
 
Mortality: 
Cumulative survival was estimated at 59-83% at 20 years, and 48-55% at 30 
years. The cohort study reporting the lowest cumulative survival of 48% at 
30 years had a higher median age of first corrective surgery, and spanned an 
earlier operative era, with the first operations being performed in 1959. On 
the other hand the study reporting the highest survival of 83% at 20 years 
included exclusively patients undergoing a biventricular repair, of whom a 
large proportion (26%) underwent an anatomical repair (atrial switch plus 
arterial switch, Rastelli, or REV procedure). The proportion of deaths which 
were sudden were reported as 13-31%. Risk factors for late death included 
systemic RV dysfunction, the presence of a complete AVSD, preoperative 
pulmonary artery banding and prolonged aortic cross clamp time at surgical 
repair (Lim et al., 2010, Rutledge et al., 2002).  
 
Morbidity: 
Atrial tachyarrhythmia occurred in up to 18% of patients, heart failure in up 
to 14%, pacemaker implantation in up to 31%, and tricuspid valve surgery in 
up to 34% of patients, although the latter was often performed at the time 
of initial surgery rather than as a later procedure in isolation.  
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3.3.2.3 Systemic RV 
A single study reported outcomes for 279 patients with any form of a 
systemic RV, as part of a larger study assessing mortality in all ACHD 
patients followed up at a single centre (Diller et al., 2015). Data were not 
differentiated further with respect to the underlying anatomy, i.e. it was 
not known how many patients were TGA-atrial switch and how many were 
CCTGA. Within the cohort 45.9% patients were female. Of the deaths 
occurring only 13% were sudden, and in fact the commonest cause of death 
was heart failure (66%). The authors adopted a different approach to 
reporting mortality compared to the other papers reviewed. Standardised 
mortality ratios (SMRs) were used, and instead of expressing survival as a 
function of time (e.g. time from initial surgery or birth), they expressed it 
as a function of age, i.e. for each congenital cardiac diagnosis they quoted 
life expectancy by expressing it as the age subgroup of the general 
population with the same mortality. So for patients with a systemic RV at 
age 40, mortality was the same as a subject from the general population at 
age 59. The SMR was 4.88 (95% CI 3.33 - 7.16), and this was the fourth-worst 
of all the congenital cardiac diagnoses studied (Eisenmenger syndrome, 
"complex" CHD e.g. unpalliated univentricular hearts, and Fontan patients 
experienced higher mortality). 
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Table 3-1 Long term outcomes in TGA-atrial switch 
Centre Year 
published 
Study description N % Female Era of initial 
surgical repair 
Baseline Mean / median 
age at baseline 
Mean / median 
follow-up 
Survival N deaths (%  
sudden or 
presumed 
arrhythmic)  
Morbidity Risk factors for 
late mortality 
(multivariate 
analysis) 
Zurich(Turina 
et al., 1989) 
1989 Retrospective single 
centre cohort 
220 33.6 1964-84 Atrial switch 
repair 
3.9y - 83% at 20y 25 total 
7 (28%) 
sudden  
PPM 10.5% at 15y 
Reoperation 9.1%  
Baffle intervention 6% 
TVR/repair 1.4% 
Heart failure 12% at 15y 
- 
Oregon(Morris 
and Menashe, 
1991) 
1991 Retrospective 
population-based 
registry 
148 23.0 1958-89 Atrial switch 
repair 
- - 61% at 15y - - - 
New York 
(Myridakis et 
al., 1994) 
1994 Retrospective single 
centre cohort 
763 - 1971-81 Atrial switch 
repair 
0.3y simple 
0.6y complex 
- At 20y 
86% simple 
64% complex 
16 total 
2 (13%) 
sudden 
SVT 13% 
Reoperation 9% 
Severe TR 11%, TVR/repair 0% 
- 
Helsinki(Kirjav
ainen et al., 
1999) 
1998 Retrospective single 
centre cohort 
100 - 1978-91 Atrial switch 
repair 
0.6y simple 
0.6y complex 
12.8y At 16y 
90% simple 
70% complex 
10 total 
 4 (40%) 
sudden 
SVT 8% 
PPM 24% 
Reoperation 3% 
Severe TR 9% 
- 
New 
Zealand(Wilso
n et al., 1998) 
1998 Retrospective single 
centre cohort 
113 - 1964-82 Atrial switch 
repair 
0.5y - 80% at 20y 19 total 
8 (42% 
sudden) 
SVT 10.7% 
PPM 4.4% 
Reoperation 8% 
Baffle intervention 7% 
- 
London (Sarkar 
et al., 1999) 
1999 Retrospective single 
centre cohort 
358 - 1965-92 Atrial switch 
repair 
2.2y 11.7y At 15y 
94% Senning 
77% Mustard 
62 total 
44 (71%) 
sudden 
SVT 38.9%  
PPM 8.8% 
Reintervention 31%   
TVR/repair 2.7% 
- 
Parma(Agnetti 
et al., 2004) 
2004 Retrospective single 
centre cohort 
703  38.4 1978-87 Atrial switch 
repair 
0.5y 19y - 5 total 
2 (40%) 
sudden 
SVT 10% 
Reoperation 1.4% 
- 
Belgium(Moon
s et al., 2004) 
2004 Retrospective 
multicentre cohort 
2833 35.4 1970-98 Atrial switch 
repair 
0.3y 17.1y 79.3% at 30y 82 total 
6 (7% sudden) 
Tachy/bradyarrhythmia 57.6% free 
at 20y 
PPM 4.3% 
Baffle intervention 6% 
Severe TR 7.4%, TVR/repair 2.5% 
- 
Barcelona 
(Dos et al., 
2005) 
2005 Retrospective single 
centre cohort 
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40.9 1973-97 Atrial switch 
repair 
1.2y 16.7y At 20y 
91% simple 
82% complex 
7 total 
5 (71%) 
sudden 
SVT 13.1% 
PPM 5.8% 
Reoperation 5.1% 
Baffle intervention 2% 
Severe TR 9% 
- 
Munich(Lange 
et al., 2006) 
2006 Retrospective single 
centre cohort 
3953 29.7 1974-01 Atrial switch 
repair 
1.2y 19.1y At 25y 
91% Senning 
76% Mustard 
42 total 
15 (36%) 
sudden 
PPM 8.9% 
Reoperation 16%  
Baffle intervention 20% 
TVR/repair 2.3% 
- 
Hanover(Gorle
r et al., 2011) 
2011 Retrospective single 
centre cohort 
2223 - 1973-
unspecified 
Atrial switch 
repair 
1.4y 16y 78% at 20y - PPM 25% 
Reoperation 39% 
- 
Glasgow(Dobs
on et al., 2013) 
2013 Retrospective single 
centre cohort 
133 33.1 1971-98 Atrial switch 
repair 
0.7y - 78% at 30y 24 total (-) - - 
                                                            
3 Excluded early perioperative mortality 
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Centre Year 
published 
Study description N % Female Era of initial 
surgical repair 
Baseline Mean / median 
age at baseline 
Mean / median 
follow-up 
Survival N deaths (%  
sudden or 
presumed 
arrhythmic)  
Morbidity Risk factors for 
late mortality 
(multivariate 
analysis) 
Rotterdam 
(Cuypers et al., 
2014) 
2014 Prospective single 
centre cohort 
864 25.2 1973-80 Atrial switch 
repair 
0.7y 35y 77% at 30y 22 total 
9 (41%) 
sudden 
SVT 28%, VT/VF 6% 
PPM 33%, ICD 6% 
Heart failure 23% severe TR 38% 
Repaired pre-1977 
Melbourne 
(Wheeler et 
al., 2014) 
2014 Retrospective single 
centre cohort 
895 46.1 - Atrial switch 
repair 
1.2y 30y - 7 total 
5 (71%) 
sudden 
SVT 30.3% 
PPM 25.8%, ICD 5.6% 
 
Denmark & 
Sweden 
(Vejlstrup et 
al., 2015) 
2015 Retrospective 
multicentre cohort 
468 31.8 1967-03 Atrial switch 
repair 
1.9y 26y 60% at 30y 176 total (-) PPM 15% 
Reoperation 7% 
Repaired pre-1980, 
presence of 
associated lesions 
 
 
 
 
 
 
  
                                                            
4 Only included patients who survived to at least the age of 10 years and were recruited into the initial cohort prior to publication of the first study in 1990 
5 Excluded patients who died before the age of 18 years 
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Table 3-2 Long term outcomes in CCTGA 
 
Centre Year 
published 
Study description N % Female Era of initial 
surgical repair 
Baseline Mean / median 
age at baseline 
Mean / median 
follow-up 
Survival N deaths (%  
sudden or 
presumed 
arrhythmic) 
Morbidity Risk factors for 
late mortality 
(multivariate 
analysis) 
Toronto (Yeh 
et al., 1999) 
1999 Retrospective single 
centre cohort 
(anatomical and 
physiological 
biventricular repair) 
127 - 1959-97 Initial surgical 
repair  
8y - 48% at 30y 35 total 
11 (31.4%) 
sudden 
VSD 86%, PS 64% 
SVT 3% 
PPM 27% 
TVR/repair 34%  
- 
Houston 
(Rutledge et 
al., 2002) 
2002 Retrospective single 
centre cohort 
(biventricular and 
univentricular repair, 
and unoperated 
patients) 
121 33.9 1952-99 Birth  4.9y 13.2y 55% at 30y 20 total 
4 (20%) 
sudden 
 
VSD 73%, PS 50%, PA 15% 
SVT 18.2% 
PPM 24.8% 
TVR 16% 
Heart failure 14% 
Presence of 
complete AVSD, 
moderate-severe 
RV dysfunction 
Boston (Hraska 
et al., 2005) 
2005 Retrospective single 
centre cohort 
(physiological 
biventricular and 
univentricular repair) 
123 39.8 1963-96 Initial surgical 
repair 
4.1y 5.2y 59% at 20y 30 total 
4 (13.3%) 
sudden 
VSD 77%, PS 39%, PA 28% 
SVT 4.9% 
PPM 37% 
TVR 22% 
Heart failure 44% 
Ebstein anomaly 
Seoul (Lim et 
al., 2010) 
2010 Retrospective single 
centre cohort 
(anatomical and 
physiological 
biventricular repair) 
167 - 1983-2009 Initial surgical 
repair 
4.1y - 83% at 20y 19 total 
4 (21.1%) 
sudden 
VSD 80%, PS 44%, PA 31% 
SVT 3.6% 
PPM 16.8% 
Reoperation 45.8% 
TVR/repair 16.8% 
Preoperative PA 
band, aortic cross-
clamp time 
Glasgow 
(Dobson et al., 
2013) 
2013 Retrospective single 
centre cohort 
(biventricular and 
univentricular repair, 
and unoperated 
patients) 
71 35.2% 1978-2009 Birth - - 79% at 20y 23 total (-) VSD 65%, PS 37%, PA 16% 
SVT 10% 
PPM 31% 
TVR 3% 
- 
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Table 3-3 Long term outcomes in systemic RV (includes TGA-atrial switch and CCTGA) 
 
Centre Year 
published 
Study description N % Female Era of initial 
surgical repair 
Baseline Mean / median 
age at baseline 
Mean / median 
follow-up 
Survival N deaths (%  
sudden or 
presumed 
arrhythmic) 
Morbidity Risk factors for 
late mortality 
(multivariate 
analysis) 
London (Diller 
et al., 2015) 
2015 Retrospective single 
centre cohort 
279 45.9 - Age >16y - 9.1y SMR 4.88 34 total 
13% sudden 
- - 
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3.3.3 Tetralogy of Fallot 
Baseline demographics: 
 There were 21 papers describing outcomes in 8824 patients. Patient gender 
was reported by 14 papers, with the overall proportion of female patients ranging 
from 36-46%. All studies reported outcomes exclusively in patients who had 
undergone surgical repair. Up to 12% of patients had an associated genetic or 
chromosomal syndrome, although this was poorly reported with only five studies 
documenting this (Park et al., 2010, Chiu et al., 2012, Hickey et al., 2009, Jonsson 
and Ivert, 1995, Bokma et al., 2015). Papers reporting outcomes from an earlier 
surgical era had a much higher proportion of patients undergoing a palliative 
shunt, with the highest being 64% (Park et al., 1987).  
 
Mortality: 
Cumulative survival ranged from 67% at 25 years in a cohort of operated and 
unoperated  patients (Olsen et al., 2010), to 98% at 30 years in patients undergoing 
repair by the modern transatrial and transpulmonary approach (Ide et al., 2009). 
One paper reported survival using SMRs, this was estimated at 2.34 (95% CI 1.73 - 
3.17) (Diller et al., 2015). Sudden cardiac death was estimated as accounting for 
up to 40% of all deaths, although in the large cohort of adult survivors of TOF this 
was only 6%, again, as for the systemic RV, heart failure was the predominant 
modality at 40%. Seven papers performed a multivariate analysis to identify risk 
factors for late mortality. Transannular patch repair and older age at surgery were 
consistently associated with an increased risk of death (Jonsson and Ivert, 1995, 
Nollert et al., 1997, Hamada et al., 2002, Bokma et al., 2015)    
 
Morbidity: 
Regarding morbidity tachyarrhythmia occurred in up to 15% of patients, and this 
was mainly supraventricular in origin. Ventricular arrhythmias generally occurred 
in 3% or less of patients, however one cohort reported it at 5.8% (Bokma et al., 
2015). This cohort consisted exclusively of adult patients undergoing PVR, and so 
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can be assumed to be older and sicker than the other cohorts reporting outcomes 
in a much younger and broader range of patients. Prevalence of severe pulmonary 
regurgitation and the need for PVR was not well characterised; the former was 
often not reported at all, and the latter was often not differentiated from other 
forms of reoperation in the survival analysis. The highest prevalence of PVR at 
time of latest follow-up was reported at just under 12% in one study (Luijten et 
al., 2015). Similarly the presence of tricuspid regurgitation was also poorly 
described, although one study exclusively of patients undergoing PVR identified 
preoperative severe tricuspid regurgitation in 10%, furthermore in a multivariate 
model consisting of age at surgery and indexed RV end systolic volume this 
conferred a higher risk of adverse postoperative outcomes with a calculated 
hazard ratio of 2.49 (95% CI 1.11 - 5.52) for a composite endpoint of death, 
sustained VT, SVT and heart failure (Bokma et al., 2015). Typically 5% or less of 
patients required PPM, the number of patients undergoing implantation of an ICD 
was poorly reported.  
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Table 3-4 Long term outcomes in TOF 
Centre Year 
published 
Study description N % Female Era of initial 
surgical repair 
Baseline Mean / 
median age at 
baseline 
Mean / 
median 
follow-up 
Survival N deaths (%  
sudden or 
presumed 
arrhythmic) 
Morbidity Risk factors for 
late mortality 
(multivariate 
analysis) 
Texas (Park et 
al., 1987) 
1987 Retrospective single 
centre cohort 
117 46.2 1962-83 Initial surgical 
repair 
25y 9.2y 84% at 15y 4 total 
0% sudden 
Palliative shunt 64% 
Arrhythmia (any) 22% 
PPM 1.8% 
Reoperation 17% 
- 
Oregon 
(Morris and 
Menashe, 
1991) 
1991 Retrospective 
population-based 
registry 
425 42.1 1958-89 Initial surgical 
repair 
0.7-6.2y - 84% at 20y - - - 
Niigata 
(Miyamura et 
al., 1993) 
1993 Retrospective single 
centre cohort 
1006 46.0 1965-71 Initial surgical 
repair 
10.4y - 94% at 20y 14 total 
1 (7%) sudden 
Reoperation 84% free at 10y - 
Stockholm 
(Jonsson and 
Ivert, 1995) 
1995 Retrospective single 
centre cohort 
165 43.6 1966-76 Initial surgical 
repair 
7y 19y 84% at 20y 40 total 
8 (20%) sudden 
Genetic syndrome 3% 
Palliative shunt 50% 
VT/VF 1.8% 
Reoperation 88% free at 10y 
Transannular 
patch repair 
Tenri (Okita 
et al., 1995) 
1995 Retrospective single 
centre cohort 
510 - 1966-90 Initial surgical 
repair 
5.6y 8.5y 95% at 20y 13 total (-) 
 
Reoperation 59% free at 20y 
Severe PR 13%, PVR 8% 
- 
Munich 
(Nollert et al., 
1997) 
1997  Retrospective single 
centre cohort 
490 45.1 1958-77 Initial surgical 
repair 
- 25.3y 89% at 30y 42 total 
15 (36%) sudden 
Palliative shunt 29% Transannular 
patch repair. 
surgical repair 
pre-1970 
Fukuoka 
(Masuda et 
al., 2001) 
2001 Retrospective single 
centre cohort 
92 - 1975-99 Initial surgical 
repair 
- - 98% at 15y - - - 
Chiba 
(Hamada et 
al., 2002) 
2002 Retrospective single 
centre cohort 
167 - 1964-75 Initial surgical 
repair 
6.4y 26y 88% at 20y 24 total 
7 (29%) sudden 
Palliative shunt 17% 
SVT 2%, VT 3% 
Transannular 
patch repair, 
older age at initial 
repair 
Mayo clinic 
(Dearani et 
al., 2003) 
2003 Retrospective single 
centre cohort (RV-PA 
conduit repair only) 
411 - 1964-92 Initial surgical 
repair 
9.6y 10.9y 73% at 15y - -  
Istanbul 
(Erdogan et 
al., 2005) 
2005 Retrospective single 
centre cohort 
64 43.8 1985-2002 Initial surgical 
repair 
20.6y 5.2y 89% at 15y 4 total 
1 (25%) sudden 
Palliative shunt 3% 
PPM 1.6% 
Reoperation 6.3% 
Severe PR 3%, PVR 6% 
Associated 
lesions, need for 
reoperation 
Toronto 
(Hickey et al., 
2009) 
2009 Retrospective single 
centre cohort 
1181 40.1 1960-98 Initial surgical 
repair 
6.7y 20y 77% at 40y 208 total (-) 
 
Genetic syndrome 12% 
Palliative shunt 53% 
AVSD, branch PA 
stenosis, DORV, 
Down syndrome 
Osaka (Ide et 
al., 2009) 
2009 Retrospective single 
centre cohort 
472 - 1960-2007 Initial surgical 
repair 
5.4y - 98% at 30y - -  
Seoul (Park et 2010 Retrospective single 734 39.5 1986-2007 Initial surgical 1.4y 12.5y 93% at 30y 40 total Genetic syndrome 3.9%  
                                                            
6 Excluded early deaths occurring at up to 1 year after initial surgical repair 
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Centre Year 
published 
Study description N % Female Era of initial 
surgical repair 
Baseline Mean / 
median age at 
baseline 
Mean / 
median 
follow-up 
Survival N deaths (%  
sudden or 
presumed 
arrhythmic) 
Morbidity Risk factors for 
late mortality 
(multivariate 
analysis) 
al., 2010) centre cohort repair 6 (15%) sudden Palliative shunt 21% 
SVT 1.2%, VT/VF 0.8% 
PPM 0.6%, ICD 0.3% 
Reoperation 47% free at 20y 
Denmark 
(Olsen et al., 
2010) 
2010 Prospective 
population-based 
registry 
381 - 1977-2006 Birth - - 67% at 25y - - - 
Oslo 
(Lindberg et 
al., 2011) 
2011 Retrospective single 
centre cohort 
570 - 1952-2008 Initial surgical 
repair 
15.3y 15.8y At 30y 
1952-69 71% 
1970-79 73% 
At 20y 
1980-89 96% 
At 10y 
1990-99 98% 
2000-09 98%  
71 total (-) 
 
-  
Taipei (Chiu 
et al., 2012) 
2012 Retrospective single 
centre cohort 
819 39.0 1970-2002 Initial surgical 
repair 
6.5y 16.9y 91% at 30y 56 total 
8 (14%) sudden 
Genetic syndrome 5.1% 
Palliative shunt 15% 
MAPCAs, previous 
palliative shunt 
Rotterdam & 
Nijmegen 
(Luijten et al., 
2015) 
2015 Retrospective 
multicentre cohort 
453 36.7 1970-2012 Initial surgical 
repair 
0.6y 15y 92% at 25y 16 total (-) Palliative shunt 12.8% 
PPM 1.1% 
PVR 11.5% 
Severe TR 0.4% 
 
Finland 
(Ylitalo et al., 
2015) 
2015 Retrospective 
population-based 
registry 
600 40.0 1962-2007 Initial surgical 
repair 
3.4y 23y 82% at 40y 82 total  
13 (16%) sudden  
Palliative shunt 25% 
Reoperation 20.2% 
 
RBH (Diller et 
al., 2015) 
2015 Retrospective single 
centre cohort 
869 45.9 - Age >16 - 9.1y SMR 2.34 54 total 
6% sudden 
-  
Amsterdam, 
Leiden, 
Radboud 
(Bokma et al., 
2015) 
2015 Retrospective 
multicentre cohort 
129 38.8 2000-2007 First PVR 33y 8.4y - 5 total 
2 (40%) sudden 
Genetic syndrome 7% 
Palliative shunt 51% 
SVT 14.7%, VT 5.4% 
PPM 5% 
Severe TR (baseline) 10.1% 
Heart failure 6.2%  
Preoperative 
tricuspid 
regurgitation, 
higher RVESV, 
older age at 
surgery7 
Malta 
(Caruana and 
Grech, 2016) 
2016 Retrospective single 
centre cohort 
758 37.3 - Initial surgical 
repair 
1.3y 26.4y 88% at 30y 7 total (-) Reoperation 29%  
                                                            
7 Multivariate analysis referred to a composite endpoint of death, arrhythmia (SVT and VT), and heart failure 
8 Excluded deaths occurring within 30 days of initial surgical repair 
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3.3.4. Differences in survival between patients with a systemic right ventricle and 
repaired Tetralogy of Fallot  
 Most studies reported cumulative survival from a baseline of initial surgical 
repair to 20-30 years of follow up, and it was therefore possible to summarise the 
differences in median survival for each diagnostic group (Table 3.5 and Figure 3.2). 
From time of initial surgical correction survival is worse in the systemic RV group, 
and within this group patients with CCTGA have the higher mortality.  
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Table 3-5 Cumulative survival from baseline for TOF, TGA-atrial switch, and CCTGA 
 
Diagnosis Cumulative survival from baseline (years) 
10 20 30 40 
Systemic RV 
TGA atrial switch 
    
Zurich (Turina et al., 1989) 87 83   
Oregon (Morris and Menashe, 1991) 64    
New Zealand (Wilson et al., 1998) 90 80   
Belgium (Moons et al., 2004) 92 89 78  
Hanover (Gorler et al., 2011) 90 85   
Glasgow (Dobson et al., 2013) 96 83 78  
Rotterdam (Cuypers et al., 2014) 84 84 77  
Denmark/Sweden (Vejlstrup et al., 
2015) 
72 65 60  
Median 
 
88.5 83 77.5  
CCTGA     
Toronto (Yeh et al., 1999) 75 48 48  
Houston (Rutledge et al., 2002) 91 75 55  
Seoul (Lim et al., 2010) 88 83   
Boston (Hraska et al., 2005) 72 59   
Glasgow (Dobson et al., 2013) 87 79   
Median 
 
87 75 51.5  
TOF     
Oregon (Morris and Menashe, 1991) 86 84   
Niigata (Miyamura et al., 1993) 97 94   
Stockholm (Jonsson and Ivert, 
1995) 
92 84   
Tenri (Okita et al., 1995) 95 95   
Munich (Nollert et al., 1997) 97 94 81  
Fukuoka (Masuda et al., 2001) 98    
Chiba (Hamada et al., 2002) 91 88   
Mayo clinic (Dearani et al., 2003) 81    
Toronto (Hickey et al., 2009) 85 82 80 77 
Seoul (Park et al., 2010) 95 93   
Oslo (Lindberg et al., 2011) 97 96 86  
Taipei (Chiu et al., 2012) 96 93 91  
Rotterdam (Luijten et al., 2015) 98    
Finland (Ylitalo et al., 2015) 91 88 84 82 
Malta (Caruana and Grech, 2016) 99 99 88  
Median 
 
95 93 86 79.5 
  
 Figure 3-2 Cumulative survival by diagnosis
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3.4 Discussion 
 
3.4.1 Mortality 
Cumulative survival from date of initial surgical correction as well as the 
single paper reporting SMRs (Diller et al., 2015) suggest that survival is poorer in 
patients with a systemic RV versus repaired TOF. This perhaps lends support to the 
hypothesis that a systemic RV has an innate predisposition to fail prematurely 
compared to a morphological LV. The reason that CCTGA patients tend to do worse 
than patients with TGA post-atrial switch can perhaps be explained by the fact 
that patients with CCTGA often have significant co-existent cardiac lesions, and 
the papers identified in this review included "all-comers", i.e. it was not possible 
to express survival purely for patients with CCTGA who did not require any form of 
additional surgical correction, who would have formed a more natural physiological 
comparator group to the TGA-atrial switch patients.   
 
 With later birth cohorts mortality appeared to decrease, and this is 
supported by the fact that surgical repair before 1980 was associated with greater 
risk on multivariate analysis for both systemic RV and repaired TOF patients 
(Nollert et al., 1997, Vejlstrup et al., 2015, Cuypers et al., 2014). However this is 
confounded by the fact that papers did not generally report cumulative survival by 
surgical era, and dates of initial surgical correction tended to be very broad. 
Establishing whether there was any social or geographical variation in mortality 
was beyond the scope of this study, mainly owing to the sheer number of 
potentially confounding variables. However, it is worth noting that the highest 
cumulative survival for CCTGA and repaired TOF was reported by centres in East 
Asia (Park et al., 2010, Chiu et al., 2012, Lim et al., 2010, Miyamura et al., 1993, 
Okita et al., 1995). Interestingly I found no studies from this region reporting long-
term prognosis in TGA-atrial switch, although there were a number of studies 
reporting outcomes in the Arterial Switch Operation for TGA, and these also 
demonstrated excellent cumulative survival at well over 90% at up to 20 years 
post-surgical repair (Lim et al., 2013, Masuda et al., 2001). Finally it is worth 
noting that only one paper reported mortality as SMR. As described previously, by 
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expressing survival as a function of age rather than time from baseline, one is able 
to mitigate both the birth cohort effect and also the disproportionate influence of 
early postoperative mortality. Therefore this method may well be a more accurate 
way of assessing survival in ACHD patients, and it is surprising that so few centres 
have adopted this approach. 
 
3.4.2 Morbidity 
 Morbidity was often not reported, and when it was it was frequently 
reported in different ways. The commonest way of reporting it was as a cross-
sectional "snapshot" at the end of the follow-up period, although for some 
outcomes, such as arrhythmia or reintervention, survival analysis was undertaken 
to ascertain the number of patients who were still free from the outcome of 
interest at a specified point in time from the original baseline. Furthermore, the 
morbidity outcomes reported tended to relate to outcomes which are generally 
easy to ascertain such as repeat surgical intervention, rather than more detailed 
functional assessment such as data derived from non-invasive imaging regarding 
e.g. the severity of ventricular dysfunction or valve regurgitation. Data were also 
lacking for morbidity outcomes such as endocarditis, stroke, venous 
thromboembolism, pregnancy, and acquired cardiovascular disease; again these 
are outcomes where status is difficult to establish as patients may not present to 
their original cardiac centre when these occur. 
 
 A few general themes came across in the analysis however. The proportion 
of patients experiencing a morbidity outcome in contemporary publications was 
higher than that reported by the oldest publications, and this was mainly driven by 
gradual attrition of patients to developing arrhythmia and haemodynamic lesions 
requiring repeat intervention. On the whole patients with a systemic RV tended to 
have higher rates of arrhythmia, pacemaker implantation, and repeat intervention 
than those with TOF. 
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3.4.3 Study limitations 
The major limitation of this study is the very heterogeneous nature of the 
cohorts that were reviewed. Despite the same underlying diagnosis, there may be 
several subtypes within that condition and a number of different operations which 
can be performed at the time of initial surgical correction. Patients vary in terms 
of the presence or absence of other associated congenital abnormalities and 
genetic syndromes, and they may or may not have had a palliative shunt prior to 
corrective surgery. Whilst all of these parameters can be reported, it is impossible 
to adjust for them in a meaningful way when performing a standard survival 
analysis (using time from surgical repair as the baseline) due to the relatively small 
numbers each subgroup. Another important limitation is that the studies reporting 
outcomes for the longest period of follow up will inevitably reflect the results of 
surgery performed several decades ago. This means that the survival data will be 
less relevant to those patients operated upon in a more contemporary era, and 
perhaps wider reporting of SMRs could avoid this problem. Other important 
limitations of this study include the lack of reporting of specific morbidity 
outcomes for each population, a paucity of functional data, the variation in the 
definition of a particular adverse outcome between different papers (for example 
one paper may have defined VT as sustained VT requiring treatment whereas 
another may have included patients experiencing brief runs of asymptomatic VT 
identified incidentally on an ambulatory ECG), and wide variations in the 
proportion of patients for whom morbidity status could be ascertained (sometimes 
data regarding the presence or absence of arrhythmia was available for less than 
half of the original cohort). Finally, there was also a degree of selection bias in 
that by only including papers which included reporting of mortality, it is possible 
that papers which looked exclusively at a particular morbidity outcome for each 
diagnosis, for example the need for PVR in TOF, were missed. However this would 
have added greatly to the complexity of what was already a difficult literature 
search.   
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3.4.4 Conclusions 
 Survival is higher in patients with repaired TOF than those with a systemic 
RV. Only one paper used SMR to assess survival; this valuable technique is thus 
under-utilised. Morbidity appears to be high, however there were major 
differences in the way outcomes were reported, and some outcomes appeared to 
be significantly under-reported. 
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Chapter 4 Long term outcomes in the 
systemic right ventricle: adult survivors 
of atrial switch surgery for transposition 
of the great arteries, and adults with 
congenitally corrected transposition of 
the great arteries 
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4.1 Introduction 
 
The morphological right ventricle supports the systemic circulation in those 
individuals with congenitally corrected transposition of the great arteries (CCTGA), 
and those who have survived atrial switch surgery (the Mustard or Senning 
procedures) for complete transposition of the great arteries (TGA-atrial switch). 
Whilst atrial switch is no longer the gold standard for management of TGA, having 
been superseded by the arterial switch operation in the late 1980s, many adult 
patients with TGA will have undergone the older procedure. 
Patients with either diagnosis are at risk of a host of complications 
associated with the systemic RV, including premature heart failure, regurgitation 
through the systemic atrioventricular valve, atrioventricular block and a need for 
permanent pacing, tachyarrhythmia, and sudden cardiac death (Warnes, 2006). 
Contemporary outcomes in patients with an SRV are poorly defined globally, 
and not at all in Scotland. As outlined in chapter 3, most published cohort studies 
of patients with TGA-atrial switch focus disproportionately upon early 
postoperative mortality, and the majority provide follow-up to only 20 years. 
Patients with CCTGA are the subject of only a handful of cohort studies. The aim 
of this study was to establish the natural history of the SRV in adult survivors of 
both conditions in a national population which had not previously been assessed.  
Of note some of the work in this chapter formed the basis for a peer-
reviewed publication in 2013 (Dobson et al., 2013). Table 4.1, Figure 4.1, and 
sections 4.3.4, 4.3.6 and 4.3.7 include some of the content of this paper in a 
modified form. All of this was exclusively my own work, and I have obtained the 
appropriate permission from the publisher.9  
                                                            
9 Reprinted with permission from the copyright holder (Elsevier) via Rightslink®, licence number 
4091060355631 
91 
 
4.2  Methods 
 
Retrospective analysis of 129 individuals aged >18 years with a diagnosis of 
TGA-atrial switch or CCTGA. Data were collected and anonymised for each 
individual from the electronic case records database as outlined in chapter 2. 
Follow-up was from the age of 18 years, and patients were censored at the time of 
their last clinic review, date of death, or date of cardiac transplant. Patients 
would also have been censored if they underwent surgery to restore the 
morphological LV to the systemic circulation however I identified no patients who 
underwent such a procedure after the age of 18 years. Patient-specific timelines 
were then constructed to formulate survival curves for time to death, 
tachyarrhythmia, pacemaker insertion, and surgical or catheter intervention. 
During each timeline patients underwent regular clinic review which allowed 
assessment of NYHA and symptom status as well as ascertainment of the 
occurrence of any clinical events e.g. a hospital admission due to tachyarrhythmia. 
For the purposes of this analysis tachyarrhythmia was defined as any 
supraventricular or ventricular tachyarrhythmia captured on ambulatory or 12-lead 
ECG recording  that was clinically significant i.e. it caused symptoms or required 
treatment. Cases were excluded if tachyarrhythmia occurred exclusively within 30 
days of cardiac surgery. Reintervention was defined as any cardiac surgical or 
percutaneous cardiac procedure occurring after baseline. Pacemaker insertion was 
defined as any permanent epicardial or endocardial pacemaker, and included those 
with cardiac resynchronisation therapy.  
Raw data were described and analysed as outlined in chapter 2. Chi square 
test using linear-by-linear association was used to assess the relationship between 
severity of tricuspid regurgitation and severity of SRV impairment. The cumulative 
probability of survival was estimated using the Kaplan Meier and life table method, 
and differences between groups were evaluated via the log rank test. Survival 
analysis was performed for the following outcomes: death or transplant, atrial 
tachyarrhythmia, surgical intervention after baseline, and pacemaker therapy. 
Cox proportional hazards models were used to identify predictors for death 
or cardiac transplant. Standardised mortality ratios for the cohort as a whole as 
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well as the subgroups of patients with TGA-atrial switch and CCTGA were 
calculated using the method described by Finkelstein and colleagues (Finkelstein 
et al., 2003). Cumulative expected mortality was calculated using vital events 
reference tables published by the National Records of Scotland showing death 
rates for the year 2011 for age-matched controls (NRS, 2011), and then summating 
the standardised mortality rates for each year of follow-up for each patient from 
age 18. All analyses were performed using IBM SPSS Statistics version 22 (IBM 
Corporation, Armonk, New York).  
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4.3 Results 
 
4.3.1 Baseline characteristics 
There were 97 adult survivors of atrial switch surgery for TGA atrial switch 
and 32 patients with CCTGA, with a median age of 29 and 33 years respectively at 
time of latest follow-up. Characteristics are outlined in Table 4.1. There were 
more male than female patients in both diagnostic groups. Most of the atrial 
switch patients had undergone a Mustard repair, only 17% had undergone a Senning 
procedure.  
The pattern of surgical intervention in the CCTGA group was more variable 
and is outlined in Figure 4.1. When surgical repair was performed this was 
physiological and directed at the correction of haemodynamically significant 
underlying lesions such as a VSD. No patients in this cohort underwent a double 
switch (anatomical repair).  
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 Table 4-1 Baseline characteristics, morbidity and outcomes in patients with TGA-atrial 
switch and CCTGA 
 TGA-atrial switch CCTGA P-value 
N 97 32  
Female (%) 33 (34) 12 (37.5)  
Age (years) 
Median  (IQR) 
 
29 (25 – 32) 
 
33 (23 – 46)  
 
0.331 
Years of follow-up 
from age 18 
Median (IQR) 
 
 
10.8 (6.5 – 13.9)  
 
 
13.2 (5.1 – 28.2)  
 
 
0.256 
Atrial switch 
operation (%) 
Mustard 
Senning 
 
 
80 (82.5) 
17 (17.5) 
 
 
N/A 
N/A 
 
Palliative shunt (%) 4 (6.2) 6 (18.8) 0.140 
Coexistent lesions 
(%) 
Dextrocardia 
VSD 
Pulmonary stenosis 
Pulmonary atresia 
Ebstein 
Coarctation 
 
 
0 
10 (10.3) 
13 (13.4) 
0 
0 
3 (3.1) 
 
 
7 (21.9) 
20 (62.5) 
10 (31.3) 
4 (12.5) 
1 (3.1) 
0 
 
 
<0.001 
<0.001 
0.002 
<0.001 
0.08 
0.314 
Prior 
tachyarrhythmia at 
baseline (%) 
 
 
7 (7.2) 
 
 
0 
 
Prior PPM at 
baseline (%) 
 
10 (10.3) 
 
6 (18.8) 
 
Prior baffle 
reintervention at 
baseline (%) 
 
 
17 (17.5) 
 
 
N/A 
 
NYHA class 
I 
II 
III 
IV 
Missing 
 
65 (67) 
20 (20.6) 
1 (1) 
2 (2.1) 
9 (9.3) 
 
21 (65.6) 
5 (15.6) 
1 (3.1) 
1 (3.1) 
4 (12.5) 
 
 
 
 
 
0.776 
Systemic tricuspid 
regurgitation (echo) 
Nil 
Mild 
Moderate 
Severe 
Replaced 
Missing 
 
 
42 (43.3) 
40 (41.2) 
13 (13.4) 
0 
0 
2  (2.1) 
 
 
2 (6.3) 
12 (37.5) 
9 (28.1) 
3 (9.4) 
2 (6.3) 
4 (12.5) 
 
 
 
 
 
 
 
 
 
 
<0.001 
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 TGA-atrial switch CCTGA P-value 
Systemic RV 
impairment (echo) 
Nil 
Mild 
Moderate 
Severe 
Missing 
 
 
26 (26.8) 
32 (33) 
18 (18.6) 
6 (6.2) 
15 (15.5) 
 
 
10 (31.3) 
13 (40.6) 
5 (15.6) 
1 (3.1) 
3 (9.4) 
 
 
 
 
 
 
0.809 
Number of patients 
assessed by MRI (%) 
 
22 (22.7) 
 
5 (10.6) 
 
Cardiac MRI data 
(mean ± SD) 
SRV EDVi ml/m2 
SRV EF % 
LV EDVi ml/m2 
LV EF % 
 
 
111 ± 8.8  
54 ± 2.3 
79 ± 6.0 
60 ± 2.6 
 
 
127 ± 18.3 
61 ± 2.6 
92 ± 11.0 
66 ± 3.3 
 
 
0.442 
0.190 
0.337 
0.220 
Number of patients 
assessed by CPET (%) 
 
33 (34) 
 
17 (53.1) 
 
CPET (mean ± SD) 
Peak VO2 ml/kg/min 
Peak VO2 % 
predicted 
Heart rate reserve 
(bpm) 
VE/VCO2 ratio 
 
 
25 ± 1.2 
68.5 ± 2.8 
 
29 ± 3.7 
36 ± 1.1 
 
 
25 ± 2.1 
62.4 ± 4.3 
 
35 ± 5.9 
34 ± 1.9 
 
 
0.937 
0.225 
 
0.374 
0.196 
Female patients with 
at least one 
successful pregnancy 
 
 
7 
 
 
3 
 
 
0.787 
N (%) PA band 
Median age (IQR) 
Median follow up 
years post PAB (IQR) 
Median velocity m/s 
(IQR) 
Median LV:SRV 
pressure 
13 (13) 
20.6 (18.0-25.8) 
 
5.8 (4.3-7.2) 
 
3.4 (2.3-3.9) 
 
0.40 (0.16-0.47) 
1 (3) 
14.2 (N/A) 
 
6.4 (N/A) 
 
3.3 (N/A) 
 
0.32 (N/A) 
 
 
 
 
 
 
 
0.124 
Medication10 (%) 
 
ACEI or A2RB 
Betablocker 
MRA 
Digoxin 
Amiodarone 
Warfarin 
 
 
15 (15.5) 
13 (13.4) 
1 (1) 
2 (2.1) 
3 (3.1) 
10 (10.3) 
 
 
6 (18.8) 
4 (12.5) 
1 (3.1) 
0  
1 (3.1) 
3 (9.4) 
 
 
0.662 
0.896 
0.406 
0.413 
0.993 
0.879 
 
                                                            
10 ACEI = Angiotensin Converting Enzyme Inhibitor, A2RB = Angiotensin 2 Receptor Blocker, MRA = 
Mineralocorticoid Receptor Antagonist 
 Figure 4-1 Coexistent lesions and initial surgery in 32 CCTGA patients
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4.3.2 Mortality  
Outcomes and cumulative survival for the 129 patients who reached the age 
of 18 years are outlined in Table 4.2 and Figure 4.2. There was no significant 
difference in survival between those patients who were TGA-atrial switch and 
CCTGA (p = 0.833). For patients with a diagnosis of TGA-atrial switch, cumulative 
survival from the baseline of 18 years of age from either death or cardiac 
transplantation was 0.93 +/- 0.03 at 10 years, 0.90 +/- 0.04 at 20 years, and 0.45 
+/- 0.32 at 30 years. For patients with CCTGA the corresponding values were 0.97 
+/- 0.03 at 10 years, 0.84 +/- 0.09 at 20 years, and 0.84 +/- 0.09 at 30 years. 
There was no significant difference in survival between Mustard and Senning 
patients (p = 0.625), although after 27 years of follow-up graphic trends favoured 
the Senning patients. A univariate analysis with a Cox proportional hazards model 
was performed to establish risk factors for death or transplant (Table 4.2). A 
higher NYHA class at baseline or the presence of severe systemic RV impairment 
were associated with a significant hazard ratio, although the confidence intervals 
were wide.  
The standardised mortality ratio was calculated for TGA-atrial switch and 
CCTGA, as well as for the SRV cohort as a whole, with results outlined in Table 4.3 
and Figure 4.3. There was an overall SMR of 4.18 for the whole cohort, with 
mortality being lower in the CCTGA cohort versus the TGA atrial switch cohort at 
2.54 versus 5.62, although clearly there is considerable overlap between the 95% 
confidence intervals. 
Table 4-2 Clinical outcomes over the follow-up period 
 TGA-atrial switch CCTGA 
Status (N %) 
Ongoing follow-up 
Lost to follow-up 
Died or transplanted 
 
86 (88.6) 
5 (5.2) 
6 (6.2) 
 
28 (87.5) 
1 (3.1) 
3 (9.4) 
Tachyarrhythmia (%) 12 (12.4) 4 (12.5) 
Reintervention (%) 19 (19.6) 3 (9.4) 
Pacemaker (%) 6 (6.2) 6 (18.8) 
AICD (%) 0 0 
CRT (%) 3 (3.1) 1 (3.1) 
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Figure 4-2 Cumulative survival from age 18 years for patients post atrial switch surgery for 
TGA and patients with a diagnosis of CCTGA 
 
95 52 10 1 - 
31 18 12 6 1 
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 Table 4-3 Univariate analysis for death or cardiac transplant in adult survivors with a 
systemic RV 
Variable Hazard ratio 95% CI P 
Gender (male) 2.28 0.47, 11.03 0.303 
Shunt 1.54 0.18, 12.89 0.692 
Initial VSD 2.37 0.62, 9.08 0.208 
Pacemaker before 
baseline 
 
2.39 
 
0.49, 11.61 
 
0.281 
Reintervention before 
baseline 
 
3.65 
 
0.96, 13.87 
 
0.057 
NYHA class 2 or higher at 
baseline 
 
14.39 
 
1.67, 124.06 
 
0.015 
At least severe SRV 
impairment at baseline 
 
10.57 
 
2.13, 52.58 
 
0.004 
At least severe TR at 
baseline 
 
2.33 
 
0.28, 19.28 
 
0.432 
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Figure 4-3 Standardised mortality ratio with upper and lower 95% confidence intervals for 
TGA atrial switch, CCTGA, and the systemic RV cohort as a whole 
   
 CCTGA All SRV TGA 
Expected deaths 0.787 1.676 0.889 
Observed deaths 2 7 5 
SMR 2.541 4.177 5.624 
Lower 95% CI 0.291 1.68 1.82 
Upper 95% CI  8.731 8.523 12.915 
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4.3.3 Morbidity 
The survival analysis for the three major adverse outcomes of arrhythmia, 
catheter or surgical intervention, or pacemaker insertion, is outlined below. 
 
4.3.3.1 Arrhythmia 
 As outlined in Figure 4.4, patients with CCTGA demonstrate low arrhythmia 
burden with cumulative survival from tachyarrhythmia being 1.00 +/- 0, 0.93 +/- 
0.07 and 0.76 +/- 0.16 at 10, 20 and 30 years from baseline. This was significantly 
better than atrial switch patients, who experienced survival of 0.83 +/- 0.05, 0.58 
+/- 0.15 and 0.58 +/- 0.15 at 10, 20 and 30 years (p = 0.028). All documented 
tachyarrhythmias were supraventricular: there were no recorded instances of 
ventricular tachycardia causing symptoms or requiring treatment (although of 
course the four sudden deaths that occurred may have been due to either 
ventricular tachycardia or fibrillation). 
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Figure 4-4 Cumulative survival from arrhythmia for patients post atrial switch surgery for 
TGA and patients with a diagnosis of CCTGA 
 
83 39 4 1 - 
30 17 12 6 1 
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4.3.3.2 Intervention 
Figure 4.5 demonstrates freedom from intervention after baseline of 18. 
This was 0.80 +/- 0.06, 0.42 +/- 0.11, and 0.42 +/- 0.11 at 10, 20 and 30 years of 
follow-up for TGA-atrial switch. For the CCTGA patients the corresponding values 
were 0.87 +/- 0.09, 0.87 +/- 0.09, and 0.65 +/-0.20 (p = 0.056).  
In the atrial switch group PA banding (11 patients) and baffle revision (8 
patients) accounted for all of the reintervention performed in adulthood.  In the 
CCTGA group intervention was due to TVR in two patients, and closure of a 
residual VSD in one.   
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Figure 4-5 Cumulative survival from reintervention for patients post atrial switch surgery 
for TGA and patients with a diagnosis of CCTGA 
 
72 38 7 1 - 
18 11 8 4 1 
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4.3.3.3 Pacemaker insertion 
There was no significant difference between the two groups for cumulative 
survival from pacemaker insertion (p = 0.564), although graphic trends suggest this 
is more frequent in the CCTGA group (Figure 4.6). Freedom from pacemaker 
insertion at 10, 20 and 30 years from baseline was 0.92 +/- 0.04, 0.86 +/- 0.06, 
and 0.86 +/- 0.06 for TGA-atrial switch, and 0.88 +/- 0.08, 0.79 +/- 0.11, and 0.69 
+/-0.14 for CCTGA. 
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Figure 4-6 Cumulative survival from pacemaker implantation for patients post atrial 
switch surgery for TGA and patients with a diagnosis of CCTGA 
 
82 40 10 1 - 
23 13 9 4 1 
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4.3.4 Cardiac function and exercise performance 
By the end of the follow-up period the majority of patients enjoyed good 
functional status as assessed by NYHA class, with 98% of atrial switch patients for 
whom data was available (85/87), and 93% of CCTGA patients (26/28) being in 
either NYHA class I or II. By transthoracic echo most patients at latest follow-up 
had no or only mild impairment of SRV function, and no or mild tricuspid 
regurgitation. More detailed assessment of ventricular function and functional 
capacity was performed by means of cardiac MRI and cardiopulmonary exercise 
testing. From cardiac MRI in 27 patients the mean ejection fraction of the SRV was 
lower in the TGA-atrial switch patients than those with CCTGA (54% versus 61%), 
although this was not statistically significant. There was no clear relationship 
between time from baseline and ventricular volumes or ejection fraction. Mean 
peak oxygen uptake for 50 patients across both groups was 25ml/kg/min, lower 
than would be expected based on the predicted values for healthy subjects of the 
same age, height and gender. There was no statistically significant difference 
between peak oxygen uptake, heart rate reserve and VE/VCO2 ratio between the 
two cohorts. 
 
4.3.5 Medication 
Relatively few patients were prescribed cardiac medication; fewer than 1 in 
5 patients were prescribed an ACE inhibitor or Angiotensin 2 receptor blocker 
which was the most commonly prescribed class of medication, generally in patients 
with documented systemic ventricular systolic dysfunction. There were 13 patients 
who were prescribed Warfarin. The indication for this was AF or atrial flutter in 11 
patients, the other 2 patients (both CCTGA) had a mechanical tricuspid valve 
replacement. There was no significant difference in prescribing of each class of 
medication between the two cohorts.  
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4.3.6 Analysis of the effect of pulmonary artery banding 
Thirteen TGA-atrial switch patients underwent a PA band for treatment of 
SRV dysfunction, one of whom later died suddenly three years post-banding. For 11 
of the 12 surviving patients (1 patient had no up-to-date imaging) the median 
follow-up period was 5.8 years. The mean gradient through the PA band was 
46.2mmHg, and the median SRV to LV peak systolic pressure ratio was 0.4. SRV 
function was either normal or mildly impaired in 9 patients, moderately impaired 
in 1 and severely impaired in 1. There was no or mild systemic tricuspid 
regurgitation in 6/11 patients, with 4 patients having moderate and 1 severe 
regurgitation. There was only one CCTGA patient who underwent a PA band. None 
of the PA banding patients were ever deemed suitable for a subsequent double-
switch. There was no significant difference in survival between the 14 patients 
across both groups who underwent PA banding compared to the 115 who did not (p 
= 0.659).   
 
4.3.7 Systemic RV impairment and tricuspid regurgitation 
The relationship between systemic RV impairment and severity of TR was 
assessed, although the two patients who underwent TVR were excluded from the 
analysis. The chi-square value for linear-by-linear association between SRV 
impairment and severity of TR was 10.064 (p = 0.002), implying a statistically 
significant correlation between the two variables 
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4.4  Discussion 
 
4.4.1 Mortality 
The cumulative probability of survival after 20 years of adult life (i.e. from 
the baseline of 18 years) was estimated at 90% for TGA-atrial switch and 84% for 
CCTGA, however the difference was not significant. When compared to the general 
Scottish population mortality as assessed by SMR is worse for both groups. Risk 
factors for mortality appeared to be the presence of severe systemic RV 
impairment or symptoms of heart failure (as evidenced by NYHA class) at age 18. 
Risk factors which are relevant at birth or in early childhood e.g. the presence of 
an initial VSD or requirement for a palliative shunt, appear to be less important by 
the time patients have survived to the age of 18 years.  
Regarding the modality of death, of the seven deaths after 18 years of 
follow-up four were sudden, and two were secondary to heart failure. This is 
similar to other studies, where sudden death and heart failure accounted for the 
majority of late deaths (Lange et al., 2006, Moons et al., 2004, Lim et al., 2010). 
Therefore strategies to identify those at risk of sudden cardiac death, and to 
manage systemic right ventricular dysfunction, will be crucial to improving 
outcomes in these patients.  
Direct comparison of cumulative survival from baseline between this cohort 
of adult survivors to those of other centres is difficult. Chapter 3 describes how 
almost all papers include early postoperative and paediatric mortality which is not 
relevant to the field of ACHD and the population I studied. However, it is possible 
to compare the SMR, and in the one paper that reported this the authors 
documented an SMR of 4.88 (Diller et al., 2015). The SMR of 4.18 for all of our 
systemic RV survivors was therefore similar. A small variation in the SMR would be 
expected: with relatively low numbers of patients in both cohorts (compared to 
e.g. studies of patients with ischaemic heart disease or heart failure), small 
variations in the absolute number of deaths will have a significant effect on the 
SMR. Furthermore it should be remembered that it was not possible to adjust for 
baseline differences such as age at repair, or other comorbidity.  
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The above all leads to the question of how survival might be improved for 
patients with a systemic RV. For those patients with TGA, the most elegant 
solution is simply to avoid having a systemic RV in the first place, and since the 
1980s this strategy has been almost universally adopted with the arterial switch 
operation. Whilst the procedure has its own collection of potential complications, 
such as problems with flow at the site of the coronary anastomoses and neo-aortic 
and neo-pulmonary regurgitation, certainly the available data suggests much lower 
mortality, rates of reintervention and arrhythmia - at least into early adulthood 
(Lim et al., 2013, Kempny et al., 2013, Tobler et al., 2010, Gorler et al., 2011). It 
remains to be seen whether the adaptation of an early aggressive strategy for 
patients with CCTGA, by which the morphological LV is connected to the systemic 
circulation, results in improved survival into adulthood. However, Brawn reports 
survival of 90% at up to 9 years in a cohort of 56 patients with CCTGA who 
underwent both types of double switch (atrial and arterial switch as well as 
Senning-Rastelli), with an early mortality of 5.6% (Brawn, 2005). Ly and colleagues 
reported 100% survival at 60 months in 20 complex CCTGA patients who underwent 
the Senning-Rastelli procedure (Ly et al., 2009). Shinoka and colleagues reported 
74.5% survival at 15 years in 15 patients undergoing atrial-arterial switch, and 80% 
survival at 16 years in 69 patients undergoing the Senning-Rastelli procedure 
(Shin'oka et al., 2007). However, with longer follow-up of up to 10 years in 65 
patients poorer survival was reported in the Senning-Rastelli group compared to 
the atrial-arterial switch (Gaies et al., 2009) Although these results are 
encouraging, the prognosis to adulthood and beyond remains to be established.  
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4.4.2 Morbidity 
 
4.4.2.1 Freedom from arrhythmia, reintervention, and pacemaker insertion 
Atrial tachyarrhythmia was common in patients with a systemic RV. 
However, it occurred significantly earlier in survivors of atrial switch surgery. This 
may be due to the extensive atrial scar tissue and potential for macro re-entry 
circuits. The relatively high prevalence of arrhythmia in both cohorts at 40 years is 
cause for concern: there are few options for pharmacological management, and 
invasive electrophysiological studies and ablation are rendered challenging by the 
abnormal anatomy.   
There was relatively high attrition from reintervention in both cohorts, with 
cumulative probability of freedom from reintervention being 57% in atrial switch 
and 53% in CCTGA patients at 30 years. In the TGA-atrial switch cohort the 
relatively high rate of baffle reintervention may be explained by the fact most 
patients had undergone a Mustard repair, and this technique is associated with a 
higher incidence of baffle obstruction than the Senning repair (Khairy et al., 2004). 
There have been no systemic AV valve replacements, and there were no adult 
patients who underwent a subsequent arterial switch procedure. In the CCTGA 
cohort physiological repair of coexistent cardiac lesions accounted for most 
intervention. Most surgery was performed during childhood, with intervention after 
18 years being far less common than intervention prior to 18 years. 
Both the TGA atrial switch group and CCTGA group had relatively high rates 
of pacemaker insertion. Although not statistically significant there was a trend 
towards this being more common in the CCTGA group. One possible reason for this 
is that the prevalence of VSD was much higher in the CCTGA group (62.5% versus 
10.3%), and surgical repair of this can often result in AV block due to the proximity 
of the VSD to the His-Purkinje system. Furthermore the anatomy of the AV node 
and His-Purkinje system in CCTGA can be highly variable (Warnes, 2006).    
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4.4.2.2 Current functional status, systemic RV impairment and tricuspid 
regurgitation, and the management of heart failure 
In keeping with the other cohort studies described previously both atrial 
switch and CCTGA patients continue to enjoy good functional status. Formal 
cardiopulmonary exercise testing demonstrated reduced maximum oxygen uptake 
compared to peak predicted, with mean peak VO2 being 25ml/kg/min for both 
atrial switch and CCTGA patients. This is in keeping with previous studies assessing 
exercise performance in patients with a systemic RV (Hechter et al., 2001, 
Fredriksen et al., 2001). There was also evidence of an abnormally high heart rate 
reserve and increased VE/VCO2 ratio, again in keeping with previous work (Diller 
et al., 2006, Diller et al., 2005, Diller et al., 2009) 
At the time this study was performed the vast majority of patients in both 
cohorts exhibited insignificant or mild SRV impairment and TR. However severe 
SRV impairment not surprisingly was a significant risk factor for death, there was a 
clear correlation between severity of SRV impairment and severity of TR - in 
keeping with the published literature elsewhere (Warnes, 2006, Scherptong et al., 
2009) - and as described previously most patients who died, died from heart 
failure. Within the cohort there was no difference between mean SRV function (as 
measured by ejection fraction from cardiac MRI) in the patients with CCTGA and 
those post TGA-atrial switch (p = 0.190).  
Approaches to management of SRV failure are controversial. Early 
intervention to a regurgitant systemic tricuspid valve has been advocated in view 
of its correlation with SRV failure. However results are poor in patients who have 
pre-existing SRV impairment, and therefore this is a prophylactic strategy rather 
than a valid treatment option for those patients who already have a failing SRV. 
Furthermore long-term prognostic data is lacking, and there are no large scale 
case-control studies (Scherptong et al., 2009, Mongeon et al., 2011, van Son et al., 
1995). Generally tricuspid valve replacement rather than repair is advocated if the 
RV is planned to remain in the systemic circulation, but this is challenging even in 
structurally normal hearts (Scherptong et al., 2009, Acar et al., 1998). The atrial-
arterial double switch or Senning-Rastelli procedures – if performed early enough 
in a centre with sufficient expertise – eliminate the problem of systemic RV 
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dysfunction and indeed tricuspid regurgitation. However results are unfavourable 
in adult patients (Benzaquen et al., 2004, Metton et al., 2010, Brawn, 2005).  
It is theoretically possible to train the LV through the placement of a PA 
band and use this effect as a treatment in its own right: higher LV pressures avoid 
septal dyskinesis which exacerbates SRV impairment, and could prevent tricuspid 
annular dilatation, thus lessening the severity of tricuspid regurgitation. From the 
small sub-cohort in our group of patients undergoing PA banding certainly most 
maintained normal or only mildly impaired SRV function. However there was no 
overall improvement in the degree of tricuspid regurgitation, where pre-PA band 
data existed. This is confirmed by two relatively large studies of 39 and 20 patients 
respectively (Winlaw et al., 2005, Cools et al., 2012), although some older, smaller 
trials suggest a modest beneficial effect on tricuspid regurgitation (Acar et al., 
1998, van Son et al., 1996, Langley et al., 2003). The biggest problem appears to 
be the development of subpulmonary LV dysfunction (Langley et al., 2003, Winlaw 
et al., 2005).  
Another potential option includes the use of classes of medication more 
usually employed in patients with left ventricular systolic dysfunction in 
structurally normal hearts. However few patients in this cohort were prescribed 
these, and this almost certainly reflects the complete absence of randomised 
control trials assessing the survival benefit of  beta-blockers and renin-angiotensin 
system blocking drugs in patients with an SRV. The decision to prescribe such 
medication is therefore made on a case-by-case basis, where the theoretical 
benefits of prescribing for systemic RV impairment are balanced against the risks 
and side effects, and the patient is made fully aware of the lack of evidence.  
Regarding device therapy only a handful of patients underwent cardiac 
resynchronisation therapy; again there is a lack of evidence for this intervention in 
patients with a systemic RV, and it may also be associated with the development 
of dysfunction of the subpulmonary left ventricle (Dubin et al., 2005, Kiesewetter 
et al., 2008). Interestingly there were no AICD insertions. Although there is a high 
risk of sudden cardiac death there are no established guidelines for formal risk 
assessment, and AICD insertion in patients with a systemic RV is based on a 
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“common sense” approach, extrapolated from studies in other populations 
(Baumgartner et al., 2010). 
Finally cardiac transplantation is an effective treatment for end stage heart 
failure in this population, however there is the problem of limited donor organ 
availability in many parts of the world, and the additional risk conferred by the 
complexity of abnormal anatomy and previous surgical intervention. Despite its 
efficacy, transplantation is sadly likely to be a realistic option for only a minority 
of patients.  
 
 
115 
 
4.4.3 Limitations 
 As with all retrospective studies our study is limited by those patients lost to 
follow up both before and after the age of 18 years, although fortunately these 
numbers were relatively small. Another group of patients missing from the analysis 
are those with asymptomatic uncomplicated CCTGA, who either have yet to 
present to medical services or are not recognised as having cardiac anatomy 
consistent with CCTGA. However, based on our own experience very few patients 
with CCTGA present after the age of 18 years, and clearly all longitudinal cohort 
studies of CCTGA have the same problem. The analysis of SMR, whilst useful, must 
always be interpreted with caution when low numbers of patients means that 
individual deaths can have a large impact on the final calculation.   
 Functional data regarding ventricular function as assessed by cardiac MRI is 
missing for a relatively large number of patients. Some patients had undergone a 
scan without formal volumetric analysis of ventricular function being performed 
(e.g. due to arrhythmia artefact), some may have been genuinely intolerant of the 
MRI scanner, and for others MRI was contraindicated owing to the presence of a 
pacemaker - none of the cardiac devices for our patients at the time the study was 
performed were MRI conditional. This will hopefully become less of an issue in the 
future as it now appears safe to scan even non-MRI conditional devices at 1.5 Tesla 
(Russo et al., 2017), although the problem of metallic artefact from leads and 
generators degrading image quality will be more difficult to address. There will of 
course be other reasons, which may include factors as mundane as administrative 
error, patient non attendance and claustrophobia. However it should be possible to 
improve upon all of these. Similar issues apply to CPET. Whilst some patients may 
genuinely be unable to exercise, again this will not apply for the majority, and 
although the percentage of patients who actually underwent CPET was higher than 
for MRI this could also be improved.  
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4.4.4 Conclusion 
Overall mortality in adult survivors of atrial switch surgery for TGA and 
CCTGA is similar, but is still higher than age and sex matched controls in the 
general population. This suggests that for the majority of patients it is actually the 
systemic RV itself, rather than the nature of any prior surgery, that determines 
long term prognosis. Systemic RV dysfunction and a higher NYHA class increase 
overall hazard for death or transplant, and most deaths are due to heart failure.  
Morbidity is substantial, with a high incidence of tachyarrhythmia, surgical 
or catheter intervention, and pacemaker insertion. Tachyarrhythmia is a particular 
problem for TGA-switch patients, occurring significantly earlier than in those with 
CCTGA. More reassuringly however significant SRV dysfunction, TR, and functional 
impairment are relatively rare at up to 40 years of age.  
Risk stratification for sudden cardiac death, and the identification of 
suitable strategies to manage SRV impairment, will be key to improving survival in 
the future. In view of the high morbidity associated with SRV impairment any 
corrective surgery which can avoid the RV having to support  a systemic circulation 
is inherently attractive, and by performing this surgery in early life one may 
achieve a more favourable prognosis to early adulthood and beyond. It will be 
interesting to see whether, similar to the transition from a strategy of atrial switch 
surgery to arterial switch surgery for TGA, in those CCTGA patients who require 
surgical repair in childhood, there will be a paradigm shift to an early anatomical 
repair. For the asymptomatic patient with uncomplicated CCTGA however, it is 
likely that there will always be a dilemma between this and conservative 
management. 
 
117 
 
Chapter 5 Long term outcomes in a 
national cohort of adult survivors of 
Tetralogy of Fallot  
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5.1 Introduction 
 
Survival for children with Tetralogy of Fallot (TOF) has improved dramatically, to 
the extent that in modern cohorts over 90% of patients can expect to survive to 
adulthood (Ide et al., 2009, Okita et al., 1995, Park et al., 2010). These survivors 
progress to make up a significant and increasing proportion of the group of 
patients cared for by adult congenital cardiac services. However, the long term 
mortality, morbidity and functional status experienced by these patients after 
adulthood is less well defined, and despite high rates of interventions such as 
pulmonary valve replacement there is no single therapy that has yet been shown to 
definitively modify prognosis in this group. Most papers outlining the long term 
prognosis for patients with TOF have performed survival analysis from time of 
initial surgical correction (Hamada et al., 2002, Nollert et al., 1997, Park et al., 
2010, Okita et al., 1995, Jonsson and Ivert, 1995, Hickey et al., 2009, Lindberg et 
al., 2011, Chiu et al., 2012), and therefore their results and conclusions are 
heavily influenced by early mortality in infancy (i.e. perioperative mortality at the 
time of initial repair), and because they typically analyse all patients operated on 
at a single institution over several decades, there is a disproportionate "birth 
cohort" effect, with the estimates of survival for the longest specified time period 
based on patients operated upon in the 1960s and 1970s. This means that any 
analysis is likely to underestimate survival for those patients with TOF who have 
already survived to adulthood, and will be of less relevance to those involved in 
the care of adult survivors of CHD. Furthermore, when identifying potential models 
for late mortality and morbidity there is a disproportionate focus on baseline 
parameters derived from the timing of the initial repair surgery (e.g. aortic 
crossclamp time), and comparatively little information regarding measures of 
current functional and performance status for example parameters derived from 
cardiac MRI and cardiopulmonary exercise testing. There is therefore a large 
unmet need for a paper assessing prognosis for exclusively adult patients with 
repaired TOF, using contemporary information derived from modern investigative 
techniques. And as with the systemic RV patients, the Scottish population has yet 
to be characterised to any extent.  
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The aim of this chapter is therefore to define the baseline characteristics of a 
large national cohort of adult patients with repaired TOF, explore the adverse 
outcomes experienced over a specified time period, identify risk factors which 
might identify patients at greater risk of these adverse outcomes, and assess the 
impact of pulmonary valve replacement.  
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5.2 Patients and methods 
 
5.2.1 Inclusion criteria 
 Since 2004 a national cardiac service for the provision of care to those 
patients with adult congenital heart disease (ACHD) has been established in 
Scotland, serving patients from a total population of 5.3 million. All surgical and 
catheter based interventions, advanced imaging and functional testing have been 
delivered through a single centre since 2009, and a computerised database 
capturing outcomes for all adult patients exists. Retrospective review of all 341 
patients with Tetralogy of Fallot who were alive and known to our service from 1st 
April 2009 until the time of data collection at 22nd September 2015 was 
undertaken.  
 
5.2.2 Follow-up 
 Status at baseline was documented along with details of past surgical 
history. Clinical events and the results of investigations including ECG, echo, 
cardiac MRI and cardiopulmonary exercise tests (CPET) were collated over the 
period of follow-up, and clinical status at the time of end of follow-up was 
recorded. Where patients had more than one investigation, changes in key 
parameters were documented. All investigations, including cardiac MRI and CPET, 
were performed according to the basic protocols outlined in chapter 2. 
 
5.2.3 Statistical analysis 
 Data were described as frequency, median, and mean values with 
interquartile range and standard deviation as appropriate. A Cox proportional 
hazards assumption was used to establish risk factors for adverse outcomes. It 
became apparent early on that there were very few events for some of the adverse 
clinical outcomes when taken in isolation, thus invalidating any attempt at 
creating a multivariate model. Furthermore some of the outcomes recorded, such 
as ICD and PVR, were premeditated clinical decisions rather than spontaneous 
events, and thus assessment of "risk" for these outcomes was somewhat 
misleading. The decision was therefore made to use a composite endpoint of 
121 
 
death, ventricular arrhythmia, and atrial arrhythmia. A univariate analysis was 
undertaken for each parameter in the first instance. Significant parameters were 
then combined in a stepwise approach to find the best fitting multivariable model, 
assuming none of the principles of a regression analysis were violated e.g. with 
multicollinearity between variables. 
 
 Calculation of SMR was performed according to the same method described 
in chapter 3 (Finkelstein et al., 2003), however the National Records of Scotland 
reference tables for 2014 were used as this reflected the later period of data 
collection (NRS, 2014). 
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5.3 Results 
 
5.3.1 Baseline characteristics 
 As demonstrated in Table 5.1, 341 adult survivors of repaired TOF were 
identified (145 female, 42.5%). Mean age at entry was 31.6 years (SD 12.3). The 
majority of patients (91.1%) had the classical form of TOF with the remaining 8.9% 
having a variant such as TOF with pulmonary atresia or TOF with AVSD.  Mean age 
at repair was 4.9 years (SD 6.8), older than would be expected in contemporary 
practice but representative of the fact that, as adults, most of our patients were 
initially repaired in the 1970s and 1980s. There were 124 patients (36.4%) who had 
undergone at least one palliative shunt procedure prior to their, and 37 patients 
(10.9%) who had been diagnosed with an underlying genetic syndrome, of whom 
the majority had either Down's (n = 16) or Di George syndrome (n = 10). We 
assessed socio-demographic status by means of the Carstairs deprivation score, and 
this showed a normal distribution, similar to the general Scottish population 
(Dobson et al., 2014).  
Prior to entry into the study 26.7% of patients (n = 91) had already undergone some 
form of surgical or catheter based intervention since their original surgical repair, 
the median age of first post-repair intervention being 15.4 years (IQR 8.2- 26.3). 
For the majority of patients this took the form of surgical intervention (n = 80), 
and the single most common intervention performed was a pulmonary valve 
replacement (PVR). Regarding other morbidity outcomes 8.5% of patients had 
already suffered at least one documented episode of cardiac arrhythmia, with 6.2% 
experiencing an atrial arrhythmia and 3.2% experiencing a ventricular arrhythmia 
(some patients experienced both). Arrhythmia occurred relatively late, with a 
median age of 31.9 years (IQR 24.1 - 44.5) for first episode of atrial arrhythmia and 
a median age of 32.7 years (IQR  19.3 - 37.2) for the first episode of ventricular 
arrhythmia. There were 13 patients who had already undergone implantation of a 
cardiac device (n = 6 dual chamber PPM, n = 2 ventricular single chamber PPM, n = 
5 ICDs), and this occurred at a median age of 34 years (IQR 22.7 - 41.3). The vast 
majority of patients were in NYHA class 1, however response to exercise capacity 
was abnormal (reduced peak VO2, elevated VE/VCO2 slope and reduced heart rate 
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response). The VE/VCO2 slope was significantly higher in females than males, but 
in contrast to what would be expected with this relationship female patients had a 
higher median peak VO2. However, on review of the raw data it appears this was 
due to three female outliers with supra-normal peak VO2, and when these patients 
were removed there was no significant difference (p=0.187).  By cardiac MRI the 
mean indexed RV and LV volumes were increased across the cohort, and median RV 
and LV ejection fraction were reduced relative to a reference population (Kawel-
Boehm et al., 2015). The difference was more marked for the RV: for patients <60 
years of age mean RVEDVi in males and females was 134 and 118ml/m2  versus  87 
and 78ml/m2, RVESVi was 75 and 61ml/m2 versus 32 and 28ml/m2, and RVEF was 
46 and 50% versus 64 and 64%. By Mann Whitney U test there was a significant 
difference in the distribution of ventricular volumes and EF between males and 
females. 
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Table 5-1 Baseline characteristics 
 All Male Female P-value 
N (%) 341 (100.0) 196 (57.5) 145 (42.5)  
Age at entry y 
Median (IQR) 
 
28.2 (21.4, 39.3) 
 
28.1 (21.2, 38.2 
 
28.2 (22.2, 40.4) 
 
0.392 
Age at repair y 
Median (IQR) 
 
3.0 (1.0, 6.0) 
 
3.0 (1.0, 6.0) 
 
3.0 (1.1, 6.0) 
 
0.346 
Time since repair y 
Median (IQR) 
 
24.2 (18.5, 32.2) 
 
24.1 (18.4, 32.2) 
 
24.2 (19.5, 32.2) 
 
0.675 
Era of initial surgery 
N (N missing) 
N (%) Pre-1970 
N (%) 1970s 
N (%) 1980s 
N (%) 1990 onwards 
 
322 (19) 
27 (8.4) 
76 (23.6) 
126 (39.1) 
93 (28.9) 
 
187 (9) 
16 (8.6) 
41 (21.9) 
72 (38.5) 
58 (31.0) 
 
135 (10) 
11 (8.1) 
35 (25.9) 
54 (40.0) 
35 (25.9) 
 
 
 
 
 
0.425 
Tetralogy subtype 
N (N missing) 
N (%) Classical 
N (%) Non-classical 
 
338 (3) 
308 (91.1) 
30 (8.9) 
 
195 (1) 
180 (92.3) 
15 (7.7) 
 
143 (2) 
128 (89.5) 
15 (10.5) 
 
 
 
0.661 
Carstairs deprivation 
category11 
N (N missing) 
N (%) 1  
N (%) 2 
N (%) 3 
N (%) 4 
N (%) 5 
N (%) 6 
N (%) 7  
 
 
336 (5) 
21 (6.2) 
36 (10.7) 
66 (19.6) 
81 (24.1) 
64 (19.0) 
38 (11.3) 
30 (8.9) 
 
 
192 (4) 
10 (5.2) 
23 (12.0) 
41 (21.4) 
49 (25.5) 
28 (14.6) 
23 (12.0) 
18 (9.4) 
 
 
144 (1) 
11 (7.6) 
13 (9.0) 
25 (17.4) 
32 (22.2) 
36 (25.0) 
15 (10.4) 
12 (8.3) 
 
 
 
 
 
 
 
 
 
0.514 
N (%) Genetic 
syndrome 
 
37 (10.9) 
 
23 (11.7) 
 
14 (9.6) 
 
0.542 
N (%) Palliative 
shunt prior to entry 
into cohort 
 
 
124 (36.4) 
 
 
68 (34.7) 
 
 
56 (38.6) 
 
 
0.734 
N (%) Redo surgery 
or intervention prior 
to entry into cohort  
 
 
91 (26.7) 
 
 
51 (26.0) 
 
 
40 (27.6) 
 
 
0.643 
Age at first redo 
surgery or 
intervention prior to 
entry into cohort y 
N (N missing) 
Median (IQR) 
 
 
 
 
88 (3) 
15.4 (8.2, 26.3) 
 
 
 
 
51 (0) 
15.2 (8.5, 23.9) 
 
 
 
 
37 (3) 
16.6 (7.9, 27.6) 
 
 
 
 
 
0.172 
N (%) Prior 
arrhythmia 
 
29 (8.5) 
 
19 (9.7) 
 
10 (6.9) 
 
0.360 
 
 
 
 
 
 
 
 
 
 
                                                            
11 1 = least deprived, 7 = most deprived 
125 
 
 All Male Female P-value 
Age at first 
arrhythmia y 
N (N missing) 
Median (IQR) 
 
 
27 (2) 
31.8 (20.6, 42.0) 
 
 
19 (0) 
31.8 (20.6, 45.0) 
 
 
8 (2) 
32.8 (23.1, 40.0) 
 
 
 
0.811 
N (%) Prior atrial 
arrhythmia 
 
21 (6.2) 
 
16 (8.2) 
 
5 (3.4) 
 
0.073 
Age at first atrial 
arrhythmia y 
N (N missing) 
Median (IQR) 
 
 
20 (1) 
31.9 (24.1, 44.5) 
 
 
16 (0) 
30.5 (20.7, 50.0) 
 
 
4 (1) 
35.5 (30.3, 40.0) 
 
 
 
0.820 
N (%) Prior 
ventricular 
arrhythmia  
 
 
11 (3.2) 
 
 
6 (3.1) 
 
 
5 (3.4) 
 
 
0.841 
Age at first 
ventricular 
arrhythmia y 
N (N missing) 
Median (IQR) 
 
 
 
10 (1) 
32.7 (19.3, 37.2) 
 
 
 
6 (0) 
33.4 (27.6, 37.2) 
 
 
 
4 (1) 
25.3 (15.0, 36.0) 
 
 
 
 
0.610 
N (%) Prior cardiac 
device 
 
13 (3.8) 
 
7 (3.6) 
 
6 (4.1) 
 
0.787 
Age at first cardiac 
device y 
N (N missing) 
Median (IQR) 
 
 
13 (0) 
34.0 (22.7, 41.3) 
 
 
7 (0) 
35.0 (30.1, 39.6) 
 
 
6 (0) 
28.2 (21.6, 40.9) 
 
 
 
0.534 
N (%) Prior PVR 62 (18.1) 35 (17.9) 27 (18.6) 0.857 
Age at first PVR y 
N (N missing) 
Median (IQR) 
 
60 (1) 
17.7 (13.8, 27.8) 
 
36 (0) 
16.3 (13.7, 25.5) 
 
24 (1) 
23.0 (14.5, 27.8) 
 
 
0.304 
Prescribed classes of 
medication N (%) 
ACE/A2RB 
Betablocker 
MRA 
Loop diuretic 
Warfarin 
Antiarrhythmic 
 
 
24 (7) 
49 (14.4) 
8 (2.3) 
16 (4.7) 
24 (7) 
12 (3.5) 
 
 
18 (9.2) 
32 (16.3) 
4 (2) 
11 (5.6) 
17 (8.7) 
8 (4.1) 
 
 
6 (4.1) 
17 (11.7) 
4 (2.8) 
5 (3.5) 
7 (4.8) 
4 (2.8) 
 
 
0.121 
0.267 
0.439 
0.612 
0.318 
0.495 
NYHA class 
N (N missing) 
N (%) class 1 
N (%) class 2 
N (%) class 3 
N (%) class 4 
 
334 (7) 
323 (96.7) 
8 (2.4) 
3 (0.9) 
0 
 
190 (6) 
183 (96.3) 
5 (2.6) 
2 (1.1) 
0 
 
144 (1) 
140 (97.2) 
3 (2.1) 
1 (0.7) 
0 
 
 
 
 
 
0.645 
Peak VO2 % 
predicted 
N (N missing) 
Mean (SD)  
 
 
182 (159) 
0.69 (0.18) 
 
 
98 (98) 
0.67 (0.17) 
 
 
84 (61) 
0.73 (0.19) 
 
 
 
0.049 
VE/VCO2 slope 
N (N missing) 
 
172 (169) 
 
93 (103) 
 
79 (66) 
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 All Male Female P-value 
Median (IQR) 33.0 (29.8, 36.0) 31.0 (28.0, 34.0) 34.0 (31.9, 37.0) <0.001 
Peak HR% predicted 
N (N missing) 
Median (IQR) 
 
174 (167) 
0.84 (0.75, 0.89) 
 
94 (102) 
0.85 (0.73, 0.91) 
 
80 (65) 
0.82 (0.77, 0.88) 
 
 
0.657 
RVEDVi ml/m2 
N (N missing) 
Median (IQR) 
 
200 (141) 
122 (100, 149) 
 
111 (85) 
127 (105, 158) 
 
89 (56) 
117 (99, 141) 
 
 
0.008 
RVESVi ml/m2 
N (N missing) 
Median (IQR) 
 
195 (146) 
63 (49, 79) 
 
108 (88) 
70 (52, 86) 
 
87 (58) 
59 (46, 74) 
 
 
0.004 
RVEF % 
N (N missing) 
Median (IQR) 
 
196 (145) 
47 (42, 54) 
 
109 (87) 
47 (40, 53) 
 
87 (58) 
49 (44, 55) 
 
 
0.013 
LVEDVi ml/m2 
N (N missing) 
Median (IQR) 
 
192 (149) 
79 (69, 91) 
 
106 (90) 
81 (72, 94) 
 
86 (59) 
76 (66, 86) 
 
 
0.007 
LVESVi ml/m2 
N (N missing) 
Median (IQR) 
 
189 (152) 
31 (25, 40) 
 
104 (92) 
33 (28, 42) 
 
85 (60) 
29 (23, 34) 
 
 
0.001 
LVEF % 
N (N missing) 
Median (IQR) 
 
189 (152) 
60 (54, 65) 
 
104 (92) 
58 (54, 62) 
 
85 (60) 
62 (56, 67) 
 
 
0.003 
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5.3.2 Adverse outcomes over the follow-up period: 
 Clinical outcomes which occurred over the study period are outlined in 
Table 5.2. 
 
Table 5-2 Clinical outcomes from 2009 - 2015 
Outcome Number of 
events 
Person y 
follow up 
Event rate per 
100 person y 
Death 712 1248.7 0.56 
Arrhythmia (any) 35 1069.7 3.27 
Ventricular arrhythmia 14 1206.4 1.16 
Atrial arrhythmia 25 1162.1 2.15 
Cardiac device13 16 1203.6 1.33 
PVR14 70 1034.7 6.77 
 
Kaplan Meier curves were employed to visually represent the cumulative survival 
from each of the clinical outcomes over the study period. Mortality for the cohort 
was low at 0.98 +/- 0.01, 0.97 +/- 0.01, and 0.93 +/- 0.04 at 2,4 and 6 years of 
follow-up (Figure 5.1). The corresponding cumulative survival from 
tachyarrhythmia was 0.91 +/- 0.02, 0.84 +/- 0.03 and 0.80 +/- 0.05, from cardiac 
device insertion was 0.96 +/- 0.01, 0.93 +/- 0.02 and 0.93 +/- 0.02, and from PVR 
was 0.80 +/- 0.02, 0.59 +/- 0.04 and 0.52 +/- 0.06 at 2,4 and 6 years (Figures 5.2 - 
5.4). 
  
                                                            
12 Of the seven deaths the causes were stroke (1), pneumonia (1), heart failure (3), sudden presumed 
arrhythmic (1), and postoperative following PVR (1). Of these patients 2 were female and 5 were male. Median 
age at death was 56.9 years 
13 11 devices were ICDs and 5 were dual chamber pacemakers 
14 The overwhelming number of interventions were PVR. Only 4 patients had surgery which involved another 
procedure (aortic root, aortic valve, or tricuspid valve surgery). Of the percutaneous intervention performed all 
were percutaneous PVRs apart from in 6 patients (these other procedures included pulmonary artery 
angioplasty, pulmonary balloon valvuloplasty, and percutaneous device closure of an ASD). 
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Figure 5-1 Cumulative survival from baseline 
 
 
 
N at risk 341 299 151 4 
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Figure 5-2 Cumulative survival from tachyarrhythmia (any) 
 
 
 
N at risk 312 260 119 3 
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Figure 5-3 Cumulative survival from cardiac device insertion 
 
 
N at risk 328 281 139 4 
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Figure 5-4 Cumulative survival from PVR 
 
 
N at risk 280 229 102 3 
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The standardised mortality ratio was calculated for the cohort using the method 
described previously in chapter 4 (Finkelstein et al., 2003). This gave an SMR of 
2.84 (95% CI 1.14 - 5.79) for the whole cohort; when analysed according for gender 
it was higher for males at 3.05 (95% CI 0.99 - 7) than females at 2.42 (95% CI 0.28 - 
8.31), however note the wide overlapping confidence intervals (Figure 5.5).   
 
Figure 5-5 Standardised mortality ratio with upper and lower 95% confidence intervals by 
gender, and for the TOF cohort as a whole 
 
 All TOF Female Male 
Expected deaths 2.47 0.83 1.64 
Observed deaths 7 2 5 
SMR 2.84 2.42 3.05 
Lower 95% CI 1.14 0.28 0.99 
Upper 95% CI  5.79 8.31 7.00 
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 As described previously the decision was made to identify variables conferring 
additional hazard for a composite endpoint of death, ventricular arrhythmia and 
atrial arrhythmia. The results of the univariate analysis and best fitting 
multivariable model are outlined in table 5.3. Note that for continuous variables 
(RVEDV, RVESV, VE/VCO2, peak VO2%, peak HR% and ECG QRS duration) the hazard 
ratio is per unit increase of the variable in question. 
Table 5-3 Univariate and multivariate predictors of a combined endpoint of death, 
ventricular arrhythmia and atrial arrhythmia 
Univariate Multivariate 
Variable Hazard ratio 95% CI P-value Hazard ratio 95% CI P-value 
Gender (male) 0.63 0.34, 1.19 0.159 0.23 0.09, 0.58 0.002 
Shunt 1.26 0.65, 2.43 0.491    
Syndrome 0.22 0.03, 1.60 0.135    
Surgery post-
1980 
 
3.47 
 
1.79, 6.74 
 
<0.001 
   
Age at repair 1.08 1.05, 1.11 <0.001 1.11 1.02, 1.21 0.022 
Classical TOF 1.02 0.24, 4.21 0.985    
Reintervention 
of surgery 
before entry 
 
 
1.07 
 
 
0.52, 2.19 
 
 
0.861 
   
RVEDV at 
baseline 
 
1.01 
 
1.01, 1.02 
 
<0.001 
 
1.02 
 
1.01, 1.02 
 
<0.001 
RVESV at 
baseline 
 
1.01 
 
1.01, 1.02 
 
0.001 
   
VE/VCO2 at 
baseline 
 
1.12 
 
1.03, 1.21 
 
0.007 
   
Peak VO2% at 
baseline 
 
0.73 
 
0.08, 6.75 
 
0.778 
   
Peak HR% at 
baseline 
 
0.10 
 
0.02, 0.66 
 
0.018 
   
ECG QRS 
interval at 
baseline 
 
 
1.02 
 
 
1.00, 1.03 
 
 
0.038 
   
 
As can be seen the best fitting multivariable model identified greater indexed 
RVEDV at baseline, female gender, and older age at repair as conferring increased 
risk for the primary outcome. 
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5.3.3 Medication 
 The prevalence of prescribed cardiac medication was low; the most 
commonly prescribed class of medication was a betablocker and this was in less 
than 15% of patients in the entire cohort. Most of these patients had a history of 
arrhythmia. Only 7% of patients were formally anticoagulated with Warfarin (data 
collection was carried out before the widespread introduction of newer direct oral 
anticoagulants), and in most cases this was due to the presence of AF or atrial 
flutter. Prescribing of renin-angiotensin system inhibitors and loop diuretics was 
even lower, and only 3.5% of patients were prescribed a dedicated antiarrhythmic 
drug (defined as a Vaughan Williams class I drug e.g. Flecainide, or a class III drug 
e.g. Amiodarone).    
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5.3.4 Analysis of the effect of pulmonary valve replacement on functional status 
 There were 70 patients who underwent PVR over the study period. Where 
patients had paired data for particular investigations (i.e. at the beginning and at 
the end of the follow-up period) the changes in ventricular volumes, exercise 
performance and electrical conduction within the ventricles (as measured by QRS 
interval duration on ECG) were assessed for those patients who underwent PVR 
relative to those who did not to gain an impression of the effects of this 
intervention (Table 5.4). There were too few adverse outcomes in each group to 
be able to reliably assess the effect of PVR on clinical endpoints such as mortality 
and arrhythmia.   
 
 
Table 5-4 Influence of PVR on ventricular volumes and exercise performance over the 
specified follow-up period 
Variable No PVR during follow-up period Had PVR during follow-up period 
Mean LVEDVi 
(SD) 
N 22 22 
Baseline 80.4 (18.6) 81.2 (22.7) 
Follow-up 81.9 (17.4) 80.8 (15.2) 
Change 1.5 (10) -0.4 (16.2) 
P 0.489 0.917 
Mean LVESVi 
(SD) 
N 20 22 
Baseline 32.1 (12.6) 36.3 (16.8) 
Follow-up 34.3 (9.6) 35.6 (9) 
Change 2.2 (9.7) -0.8 (10.6) 
P 0.335 0.735 
Mean LVEF 
(SD) 
N 19 22 
Baseline 58.2 (6) 56.1 (9.6) 
Follow-up 57.6 (8.3) 56.6 (5.5) 
Change -0.6 (6.9) 0.5 (6.8) 
P 0.720 0.757 
Mean RVEDVi 
(SD) 
N 23 27 
Baseline 116.1 (29.6) 144.5 (28.2) 
Follow-up 116.0 (26.4) 112.4 (37.2) 
Change -0.1 (19.7) -32.1 (32.3) 
P 0.983 <0.001 
Mean RVESVi 
(SD) 
N 21 27 
Baseline 62.1 (20.1) 80.0 (21.8) 
Follow-up 60.6 (20.1) 62.4 (24.2) 
Change -1.5 (13.6) -17.7 (17.3) 
P 0.625 <0.001 
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Mean RVEF 
(SD) 
N 21 27 
Baseline 47.9 (7.9) 45.6 (8.8) 
Follow-up 49.8 (10) 44.1 (13.1) 
Change 1.9 (5.7) -1.5 (11) 
P 0.132 0.489 
Peak VO2 as a 
% of predicted 
(SD) 
N 37 34 
Baseline 0.73 (0.17) 0.65 (0.16) 
Follow-up 0.67 (0.16) 0.63 (0.15) 
Change -0.05 (0.15) -0.02 (0.18) 
P 0.032 0.583 
VE/VCO2 slope 
(SD) 
N 34 34 
Baseline 32.7 (4.5) 34.7 (5.6) 
Follow-up 30.7 (5.5) 33.2 (4.5) 
Change -2.0 (4.9) -1.5 (4.6) 
P 0.021 0.070 
Peak HR as a % 
of predicted 
(SD) 
N 36 34 
Baseline 0.81 (0.10) 0.83 (0.11) 
Follow-up 0.81 (0.11) 0.81 (0.1) 
Change 0 (0.1) 0 (0.1) 
P 0.840 0.111 
ECG QRS 
interval (SD) 
N 143 70 
Baseline 143.7 (23.4) 153.7 (25.4) 
Follow-up 144.9 (25.4) 149.8 (28.0) 
Change 1.2 (10) -3.8 (13.3) 
P 0.146 0.019 
 
As can be seen, with no PVR during follow-up there was no significant change in 
ventricular volumes or ejection fraction. In patients who underwent PVR over the 
follow-up period there was a significant reduction in both RVESV and RVEDV, 
although the combined effect of this appeared to cancel out any significant change 
in RVEF. PVR was not associated with a significant change in LV volumes or EF. 
Regarding exercise test data, peak VO2 declined significantly in those patients who 
did not undergo a PVR over the follow-up period, but did not change significantly 
in those that did. Interestingly VE/VCO2 slope decreased slightly in both groups, 
although this was not significant for the PVR group. There was no significant 
change in peak HR as a percentage of the predicted value in either group. On 
review of ECG data interventricular conduction delay (as measured by QRS interval 
duration) decreased significantly following PVR, and displayed a trend towards 
increasing in those who did not undergo PVR.    
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5.4 Discussion 
 
5.4.1 Survival and morbidity 
 Over a follow-up period of over 6 years the number of deaths in a large 
cohort of patients with repaired TOF was low, corresponding to an event rate of 
0.56 per 100 person-years. Morbidity was much higher, with event rates of 
documented arrhythmia of 3.27 per 100 person-years, ventricular arrhythmia of 
1.16 per 100 person-years, atrial arrhythmia of 2.15 per 100 person-years, device 
implantation of 1.33 per 100 person-years, and PVR of 6.77 per 100 person-years. 
The variables associated with adverse outcomes in the multivariate analysis were 
indexed RVEDV, female gender, and older age at repair. A higher RVEDV is the 
inevitable consequence of a volume loaded RV in the setting of severe pulmonary 
regurgitation, and as the RV dilates so there is adverse cardiac remodelling, 
greater scarring and fibrosis. This creates the substrate for macro-reentrant 
circuits and arrhythmia, and deleterious RV-LV coupling ultimately results in the 
development of left ventricular dysfunction and biventricular failure (Babu-
Narayan et al., 2006, Apitz et al., 2009). In fact RVEDV is already a key 
determinant in when to offer a patient PVR, since as RV volumes increase past a 
threshold of 150-160ml/m2 so the RV is less likely to normalise even with PVR 
(Geva, 2013, Buechel et al., 2005, Geva et al., 2010, Frigiola et al., 2008).  
Regarding female gender it must be remembered that this is a single cohort, the 
confidence intervals were relatively wide, and this only became significant with 
indexed RVEDV in the model. However, it is an interesting finding, and certainly 
worthy of further study. There have been comparatively few papers to identify a 
link between gender and adverse outcomes in ACHD as a whole, let alone TOF in 
isolation. However there is compelling evidence to suggest that even when indexed 
to body surface area there are significant gender differences in ventricular 
dimensions and function as well as electrical conduction through the ventricles, 
and perhaps this is the mechanism by which female patients are more likely to 
experience outcomes such as arrhythmia (Sarikouch et al., 2011) . One of the few 
studies which has looked at the effects of gender in ACHD identified that women 
with ACHD were more likely to have pulmonary hypertension, and less likely to 
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receive an ICD compared to men (Verheugt et al., 2008). The mechanisms for this 
are likely to be complex, however in the field of acquired heart disease it is well 
established that women are at greater risk of sudden cardiac death, often present 
with atypical symptoms, and may be subject to gender bias (the Yentl effect).   
With older age at repair patients will have been exposed to cyanosis and increased 
blood flow through the pulmonary circulation for a longer period of time, they are 
also more likely to have been repaired in an older era with less advanced 
myocardial protection intraoperatively, and will almost certainly have experienced 
a degree of failure to thrive. All of the above might reasonably be expected to 
increase myocardial scar, have a deleterious effect on cardiac function, and 
indeed this variable has been identified as conferring hazard in other TOF cohorts 
(Nollert et al., 1997, Bokma et al., 2015, Hamada et al., 2002).  
It is also worth noting that although it was not robust enough to be included in the 
multivariable model, there was a univariate association between VE/VCO2 and the 
primary outcome. The VE/VCO2 ratio is a marker of reduced efficiency of 
ventilation and gas exchange during exercise, is thus associated with sicker hearts, 
and has been consistently associated with adverse outcomes in repaired TOF in a 
number of previous studies (Giardini et al., 2007, Giardini et al., 2009a, Buys et 
al., 2012), and of all the parameters derived from CPET the VE/VCO2 ratio appears 
to be the most powerful at establishing prognosis.   
Finally, comparatively few patients were prescribed cardiac medication when 
compared to contemporary cohorts of patients with acquired conditions such as 
ischaemic heart disease. This reflects the absence of any evidence for the use of 
such medication in improving outcomes in repaired TOF. In this cohort generally 
the only patients for whom these medications were prescribed were older patients 
who had developed secondary pathology for which these medications were 
indicated; such as LV systolic dysfunction, ischaemic heart disease and 
tachyarrhythmia. It would be interesting to ascertain whether patients with 
repaired TOF and an indication for such treatments respond as well to these drugs 
as those patients without TOF but who with the same indication. 
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5.4.2 The effect of pulmonary valve replacement 
 Any interpretation of the results in table 5.4 needs to take into the account 
that the decision to proceed to elective PVR – as with other major surgical 
operations – is nuanced, and based on multiple clinical parameters. Both the 
European and American guidelines (Baumgartner et al., 2010, Warnes et al., 2008) 
suggest that this should be based on the presence of symptoms (including an 
objective reduction in exercise capacity as measured by CPET), haemodynamic 
parameters such as the degree of RV dilatation or a reduction in systolic function, 
and the development of arrhythmia. These factors must be balanced against other 
factors such as comorbidity, the number of previous sternotomies, and of course 
individual patient preference regarding intervention. Thus the two groups of 
patients can be characterised as follows: the group of patients who underwent PVR 
will have had severe pulmonary regurgitation, a dilated RV, and reduced exercise 
capacity. On the other had in the group of patients who did not undergo PVR will 
exhibit a dichotomy between those patients who have reaped the benefits of an 
excellent surgical repair (with minimal pulmonary regurgitation and RV dilatation, 
and good exercise capacity), and those patients who technically meet the 
indications for PVR (and will thus have the same characteristics as the PVR group), 
but due to factors such as comorbidity, patient preference, or loss to follow-up did 
not undergo PVR over the follow-up period.  
At baseline the PVR group had higher indexed RVEDV and RVESV, slightly lower 
RVEF, and lower peak VO2 than the non-PVR group. Over the follow-up period, the 
effect of PVR was to bring about a significant decrease in RVEDV and RVESV, and 
also a reduction in ECG QRS duration – as RV volumes decrease so there is less 
delay in depolarisation throughout the ventricle, and less electromechanical 
decoupling from the LV. This confirms findings from other cohorts (Cavalcanti et 
al., 2013, van Huysduynen et al., 2005).  
The effect of PVR on the left ventricle and exercise capacity has been less well 
studied. In this cohort PVR brought about no significant change in LV volumes or 
function, in contrast to one single centre study of 39 patients which saw an 
improvement in LVEF driven by a reduction in LVESV - however it should be noted 
that this increase was only significant in patients with an LVEF of less than 45% 
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preoperatively - significantly lower than mean LVEF of 56% in this cohort (Tobler et 
al., 2012). I found only two papers which reported data from CPET post PVR. One 
described a very small reduction in VE/VCO2 but no change in peak VO2 (Frigiola 
et al., 2008), another found no change in peak VO2 (Ho et al., 2015). Neither 
paper assessed change in exercise parameters in a control group. I found no 
significant change in either peak VO2 or VE/VCO2 in the PVR group. Although peak 
VO2 decreased significantly in the no-PVR group, which might suggest that PVR at 
least helps to halt the decline in exercise capacity that may occur in untreated 
pulmonary regurgitation, this is not supported by the change in VE/VCO2, which 
decreased in the non-PVR group (i.e. one would expect it to increase if there was a 
genuine reduction in peak VO2 due to cardiovascular limitation of exercise). 
Ultimately, there is no evidence to suggest that exercise capacity is dramatically 
improved by PVR, regardless of the undeniable improvement in RV volumes.   
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5.4.3 Study limitations 
 The study used a composite endpoint due to the low event rate over the 
follow-up period. Whilst this is a valid way of increasing statistical power, and has 
been employed previously in contemporary studies of adult survivors of TOF 
(Gatzoulis et al., 2000, Bokma et al., 2015)  there remain the problems of 
weighting the analysis in favour of some adverse outcomes over others, and 
increasing the likelihood of a type 1 error.  
This study was based upon retrospective data, and thus the univariate and 
multivariate predictors of adverse outcomes need to be validated through 
prospective follow-up of a larger cohort. Finally, not all of the patients had cardiac 
MRI and CPET performed, and for those patients who underwent PVR it was not 
always the case that  paired CPET and MRI data were available (that is to say that 
a patient had both MRI and CPET performed before and after valve replacement). 
In some cases this was unavoidable, for precisely the same reasons as outlined in 
chapter 4 - artefact preventing quantitative ventricular analysis, presence of a 
non-MRI conditional cardiac device, patient claustrophobia, etc. The other issue is 
that these were all clinical rather than research tests, and in a resource limited 
environment such as the NHS clinical elective investigations may of course at times 
be postponed or cancelled in favour of more urgent cases. However, improving the 
proportion of patients who undergo these recommended investigations is clearly an 
important issue which has become evident as a result of this study, and one which 
the service must address in the future. 
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5.4.4 Conclusion 
 In a large cohort of adult survivors of repaired TOF mortality is low, 
although event rates of morbidity outcomes such as arrhythmia, cardiac device 
insertion, and especially PVR are relatively high. Consistent markers for adverse 
outcomes are the presence of RV dilatation as assessed by indexed RVEDV, older 
age at primary repair, and female gender. PVR - by far the commonest 
intervention - was associated with a significant reduction in RV volumes and 
interventricular conduction delay, and by extrapolation could conceivably avoid 
adverse clinical outcomes such as arrhythmia. However due to the low mortality 
rate in this cohort, and with a high number of confounding factors, proof that PVR 
definitively modifies prognosis in this patient group is likely to remain elusive.   
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Chapter 6 Improving risk stratification of 
patients with repaired Tetralogy of Fallot 
using cardiac MRI and cardiopulmonary 
exercise testing    
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6.1 Introduction 
 
In the previous chapter I described the natural course of adult patients with 
repaired TOF, and defined the adverse outcomes experienced over the follow-up 
period. It became apparent that it was difficult to risk stratify patients, and in 
particular those patients who were likely to develop sustained ventricular 
arrhythmia, which can be devastating as it may present as sudden cardiac death 
(SCD). The electrophysiological mechanisms behind this are likely to be 
multifactorial, however ventricular scar and fibrosis can provide the substrate for 
this to develop (Friedli, 1999, Steeds, 2004, Khairy et al., 2009).  
Cardiac MRI is regarded as the gold standard for the serial non-invasive 
assessment of patients with TOF: it provides detailed and reproducible information 
on the structure and function of the heart post surgical repair, and crucially, with 
respect to ventricular arrhythmia, it allows the determination of the presence and 
extent of myocardial fibrosis as assessed by Late Gadolinium Enhancement (LGE). 
LGE has been associated with a greater risk of adverse outcomes in patients with 
repaired TOF in other cohorts (Babu-Narayan et al., 2006), however the data is 
relatively old and relates to patients who were repaired in an earlier surgical era - 
perhaps with less perioperative myocardial protection during repair. A significant 
proportion of patients with repaired TOF in this Scottish cohort had undergone 
cardiac MRI, but no formal attempt had been made to establish whether or not 
LGE could improve the recognition of patients at risk of adverse outcomes.  
The aim of this study therefore was to quantify the amount of RV and LV 
LGE in adult survivors of TOF in a contemporary cohort, and together with the 
other parameters derived from cardiac MRI and CPET establish its utility in 
identifying  those patients at greater risk of adverse clinical endpoints. Of note  
tables 6.1-6.3, and figures 6.1-6.4, whilst exclusively the work of the author, have 
been published elsewhere (Dobson et al., 2017) and so the appropriate permissions 
were sought and granted by the publisher15.  
  
                                                            
15 Reprinted with permission from the copyright holder (John Wiley and Sons) via Rightslink®, licence number 
4087210053080 
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6.2 Methods 
 
6.2.1 Patient eligibility and data collection 
 This was a single centre cohort study. At the time of data collection there 
were 376 adult survivors of TOF. Of these patients 239 had undergone CMR 
scanning, and 118 of these had contrast enhanced CMR with the administration of 
Gadolinium as Gadolenic acid  (Dotarem®), with 114 scans of sufficient quality to 
include in the final analysis (Figure 6.1).  
 
 
Figure 6-1 Eligibility criteria 
 
 
 
 Baseline demographics included date of birth, gender, details of surgical repair 
including palliation, and date of death or last review. Morbidity outcomes 
376 patients with Tetralogy of Fallot
239 patients with at least one CMR 
scan
118 patients administered 
gadolinium contrast
114 patients included in final analysis
3 confirmed myocardial infarcts 
excluded from LV LGE analysis
2 scans missing from archive
2 scans poor quality LGE
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documented were atrial arrhythmia (defined as sustained atrial tachycardia, 
supraventricular tachycardia, atrial flutter, or atrial fibrillation), clinically 
significant ventricular arrhythmia (defined as sustained ventricular tachycardia or 
ventricular fibrillation), the need for cardiac device insertion (permanent 
pacemaker or implantable cardioverter-defibrillator), and the need for 
percutaneous or cardiac surgical reintervention. Information on functional status 
included NYHA class and parameters derived from ECG, echocardiography, CMR 
and cardiopulmonary exercise testing (CPET). 
 
6.2.2 Cardiac MRI 
 All CMR scans were performed at the host institution at 1.5 Tesla field 
strength using a Siemens Magnetom Avanto (Siemens AG, Erlangen, Germany) with 
a 12-element phased array cardiac surface coil. A standard imaging protocol was 
followed for all patients as outlined in chapter 2. Following this, LGE images were 
obtained 10-15 minutes after the administration of 0.15mmol/kg of Gadolenic acid 
(Dotarem®).  The entire LV and RV were imaged using a phase sensitive inversion 
recovery sequence in contiguous short axis views from the level of the AV valves to 
the apex, and then in long axis views (Mordi et al., 2014). LV and RV volumes at 
end diastole and end systole had been quantified using computer assisted 
planimetry and indexed to body surface area by a single analyst with over 5 years 
of CMR experience (HW). Pulmonary regurgitant fraction was calculated as a 
percentage of regurgitant volume divided by RV stroke volume on the flow-
mapping sequences. LV LGE was formally quantified as late Gadolinium mass and 
expressed as a percentage of the total LV mass using the 5 SD from remote 
myocardium method (Mordi et al., 2014). The degree of RV LGE was expressed 
using the semiquantitative RV seven segment model proposed by Babu-Naryan and 
colleagues, as shown in Figure 6.2 (Babu-Narayan et al., 2006). 
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Figure 6-2 Quantification of RV LGE 
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6.2.3 Statistical analysis 
 The first part of the study involved a cross-sectional analysis of the cohort 
at the end of the study period. Means, medians and distributions were compared 
using the techniques described in chapter 2. Correlation for normally distributed 
data was assessed using the Pearson product-moment correlation coefficient, and 
the Spearman rank correlation coefficient if non-normal. Tests of association 
between nominal and continuous data were performed using one way ANOVA or 
the Kruskal Wallis test according to whether the distribution of the data was 
normal or non-normal.  
 The second part comprised a survival analysis from the date of CMR scan to 
the end of the follow-up period. This was initially undertaken using a univariate 
Cox regression model from the date of CMR scan. Because of the low number of 
adverse events (and no deaths) over the follow-up period I decided to use a 
composite outcome, which included atrial arrhythmia, sustained ventricular 
arrhythmia, ICD implantation or heart failure admission. PVR was not included in 
this composite outcome, for the reasons outlined in chapter 5. If a baseline 
variable was associated with a greater risk of the composite outcome in the 
univariate model to a level of significance of p < 0.2, the analysis was repeated 
with age at the time of scan as a covariate in order to adjust for the effect of 
older age on the likelihood of experiencing an adverse event - the reasons for this 
became apparent during the course of the study and are outlined below. Due to 
the relatively low number of adverse outcomes it was not possible to use more 
than two covariates in the model. 
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6.3 Results 
 
6.3.1 Baseline characteristics 
 Characterisation of the cohort at the end of the study period is presented in 
table 6.1. As mentioned previously, an adverse event was defined as an episode of  
atrial arrhythmia, sustained ventricular arrhythmia, ICD implantation or heart 
failure admission. The breakdown of these adverse outcomes was as follows: atrial 
arrhythmia in 15 (13.2%), sustained ventricular tachycardia in 4 (3.5%), ICD 
implantation in 6 (5.3%) and heart failure admission in 3 (2.6%), i.e. a total of 27 
adverse events occurred in 21 patients.  
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Table 6-1 Characteristics of cohort 
 All patients Patients with no 
adverse events 
Patients with 
adverse events  
P 
N (%) 114 93 (81.6) 21 (18.4)  
Male/Female 64/50 51/42 13/8 0.557 
Median age at 
repair y (IQR) 
 
2 (1 - 4) 
 
2.5 (1.3 - 4.2) 
 
3.7 (1.9 - 9.8) 
 
0.029 
Median age at 
scan y (IQR) 
 
29.5 (23.3 - 38.8) 
 
26.8 (22.3 - 36.7) 
 
42.7 (32.1 - 46.7) 
 
<0.001 
TOF subtype N 
(%) 
Classical 
Non-classical 
 
 
107 (93.9) 
7 (6.1) 
 
 
86 (92.5) 
7 (7.5) 
 
 
20 (95.2) 
1 (4.8) 
 
 
 
0.656 
Era of initial 
surgical repair N 
(%) 
1960-1969 
1970-1979 
1980-1989 
1990-1999 
2000- 
Missing 
 
 
 
3 (2.6) 
29 (25.4) 
45 (39.5) 
29 (25.4) 
2 (1.8) 
6 (5.3) 
 
 
 
2 (2.2) 
20 (21.5) 
36 (38.7) 
29 (31.2) 
2 (2.2) 
4 (4.3) 
 
 
 
1 (4.8) 
9 (42.9) 
9 (42.9) 
0 
0 
2 (9.5) 
 
 
 
 
 
 
 
 
0.001  
Palliative shunt N 
(%) 
 
46 (40.4) 
 
37 (39.8) 
 
9 (42.9) 
 
0.275 
Number of redo 
sternotomies (%) 
0 
1 
2 
3 
 
 
52 (45.6) 
52 (45.6) 
8 (7.0) 
2 (1.8) 
 
 
44 (47.3) 
43 (46.2) 
5 (5.4) 
1 (1.1) 
 
 
8 (38.1) 
9 (42.9) 
3 (14.3) 
1 (4.8) 
 
 
 
 
 
0.223  
Had at least one 
PVR (%) 
 
60 (52.6) 
 
47 (50.5) 
 
13 (61.9) 
 
0.348 
NYHA class N (%) 
1 
2 
3 
4 
 
107 (93.9) 
5 (4.4) 
1 (0.9) 
0 
 
90 (96.8) 
3 (3.2) 
0 
0 
 
17 (81.0) 
2 (9.5) 
1 (4.8) 
0 
 
 
 
 
0.032  
 
ECG median 
resting HR (IQR) 
 
 
72 (62 - 79) 
 
 
74 (62 - 80.5) 
 
 
68 (61.5 - 75) 
 
 
0.117 
ECG QRS duration 
ms (IQR) 
 
150 (134 - 164) 
 
148 (133 - 161) 
 
165 (141 - 186.75) 
 
0.023 
CPET median VO2  
as % predicted 
(IQR) 
 
 
71 (60.25 - 80) 
 
 
72 (62 - 80.5) 
 
 
63 (49 - 75) 
 
 
0.078 
CPET median 
VE/VCO2 slope 
(IQR) 
 
 
32 (28.63 - 35.75) 
 
 
31.5 (28 - 34.6) 
 
 
35 (32 - 37.8) 
 
 
0.012 
CPET median 
peak HR as % 
predicted (IQR) 
 
 
82 (75.5 - 89) 
 
 
83.5 (77 - 89) 
 
 
73 (67 - 90) 
 
 
0.091 
151 
 
CMR median 
RVEDVi ml/m2 
(IQR) 
 
 
125 (100 - 152) 
 
 
121 (99 - 144) 
 
 
141 (121 - 168) 
 
 
0.048 
CMR median 
RVESVi ml/m2 
(IQR) 
 
 
64 (49.75 - 83) 
 
 
61 (46.5 - 77.5) 
 
 
79 (55.5 - 99) 
 
 
0.036 
CMR median RVEF 
% (IQR) 
 
48 (43 - 54) 
 
49 (44 - 54.5) 
 
47 (37 - 53) 
 
0.092 
CMR median 
LVEDVi ml/m2 
(IQR) 
 
 
80.5 (72 - 93) 
 
 
80 (70.5 - 91) 
 
 
85 (74.5 - 108.5) 
 
 
0.071 
CMR median 
LVESVi ml/m2 
(IQR) 
 
 
32 (27 - 41) 
 
 
31 (27 - 40) 
 
 
37 (29 - 51) 
 
 
0.022 
CMR median LVEF 
% (IQR) 
 
59 (54.75 - 64) 
 
60 (55.5 - 65) 
 
56 (52 - 60) 
 
0.025 
Median 
pulmonary 
regurgitant 
fraction % (IQR) 
 
 
 
28.5 (10.75 - 38.5) 
 
 
 
28 (10.5 - 36.5) 
 
 
 
31 (12.5 - 46) 
 
 
 
0.163 
Median RV LGE 
score /20 (IQR) 
 
6 (5 - 7) 
 
6 (4 - 6.5) 
 
6 (5 - 7.5) 
 
0.069 
Median LV LGE 
mass % (IQR) 
 
1.75 (0.7 - 3.23) 
 
1.55 (0.5 - 2.95) 
 
2.9 (1.7 - 4.2) 
 
0.008 
 
 The majority of patients were male, most were repaired in the 1980s, and 
under half had received a palliative shunt prior to complete repair. Symptomatic 
dyspnoea was rare, with almost 95% of patients in NYHA class 1. Across the cohort 
both the median peak VO2 and heart rate response to exercise were reduced 
compared to the predicted values, and median VE/VCO2 was slightly elevated at 
32. Regarding CMR data, the median indexed RV volumes were elevated in 
comparison to a reference population (Maceira et al., 2006, Kawel-Boehm et al., 
2015) although median LV volumes were comparable, with a slight reduction in 
LVEF driven by a rise in LVESVi. Approximately 22% of patients had negligible 
pulmonary regurgitation (RF <5%), either due to prior PVR which still retained good 
function, or an initial surgical repair which preserved the function of the 
pulmonary valve. The remainder had significant pulmonary regurgitation with a 
median regurgitant fraction of almost 30%.  
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6.3.2 Distribution and extent of LGE 
 All patients had at least some RV LGE evident. Median RV LGE score was 
6/20, and the pattern of LGE was consistent, being almost always seen at the 
surgical sites of the RVOT and VSD patch, and the insertion points of the RV on to 
the LV (Figure 6.3). Median LV LGE mass expressed as a percentage of total LV 
myocardial mass was low at 1.75%, and in almost all cases LGE was confined to in 
or around the insertion points of the RV on the interventricular septum. Only 9 
patients had no LV LGE evident.  There were three patients with overall 
significantly higher LGE mass than the remainder of the cohort, all of whom had 
undergone myocardial infarction. 
 
 
Figure 6-3 Distribution of LGE within the right ventricle 
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As outlined in figure 6.4, when the cohort was divided into quartiles16, there was a 
clear relationship between the RV LGE score and age at scan and age at repair. 
There was also a statistically significant difference between the LV LGE mass and 
age at scan and age at repair.  
Figure 6-4 Relationship between age at scan / age at repair and right and left ventricular 
LGE 
 
  
                                                            
16 For each panel, from left to right, the data is presented as the lowest quartile (Q1), the interquartile range 
(Q2 and Q3), and the highest quartile (Q4) 
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The Spearman rank coefficient was used to identify whether there was any 
correlation between parameters derived from CMR and from CPET. There was no 
significant correlation between either RV LGE score and LV LGE mass and the 
following variables: peak VO2, peak VO2 as a percentage of the peak predicted 
value, VE/VCO2 slope, and peak HR as a percentage of the peak predicted value. 
There was weak negative but significant correlation between RV LGE score and 
RVEF (r = -0.193, p=0.036). LV LGE score and LVEDVi were weakly correlated (r = 
0.216, p=0.021), as were LV LGE score and LVESVi (r = 0.201, p=0.032). RV LGE 
score and LV LGE mass weakly correlated with each other (r = 0.267, p=0.004). 
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6.3.3 Adverse events and LGE: a cross-sectional analysis 
 The next step in the analysis was to compare the characteristics of the 21 
patients who had experienced an adverse event at any time (atrial arrhythmia, 
sustained ventricular arrhythmia, ICD implantation or heart failure admission) with 
the 93 patients who had not (table 6.1). The patients who had experienced an 
adverse event were significantly older both at age of repair and age at CMR scan. 
They were more likely to have symptomatic breathlessness, have a wider QRS 
duration on ECG, and have a higher VE/VCO2 ratio on CPET. The RVEDVi and 
RVESVi were significantly higher as was LVESVi, although LVEDVi did not quite 
approach statistical significance. Consequently LVEF (but not RVEF) was lower in 
this group. They displayed a higher LV LGE mass, and there was the suggestion that 
they also had a higher RV LGE score, although this did not reach significance at the 
0.05 level. 
 
 
6.3.4 Survival analysis 
 The final step was to establish which factors were associated with an 
increased hazard of a composite outcome of adverse cardiac events at a mean 
follow up of 2.35 years (SD 1.29) from time of scan, and whether these included RV 
or LV LGE. Of the 21 patients who experienced an adverse outcome, 10 had 
experienced it before the time of baseline CMR scan. This left 11 patients who 
could be included in the survival analysis. The results of the univariate analysis are 
outlined in table 6.2. A higher RVEDVi, LVEDVi, older age at scan, NYHA class, and 
LV LGE mass conferred risk for an adverse event, as did a lower RVEF, LVEF and 
peak HR during CPET (expressed as a percentage of the peak predicted value). Of 
note RV LGE score did not. As the patients who experienced adverse events tended 
to be significantly older than those who did not, it was decided to repeat the 
analysis adjusting for age at scan as a covariate, and the results are shown in table 
6.3. Briefly, RVEDVi, LVEDVi, RVEF, LVEF and NYHA class all continued to be 
significantly associated to the development of adverse outcomes, as well as having 
a higher number of redo sternotomies or a lower peak VO2 during CPET. LV LGE 
mass and peak HR as a percentage of the predicted value during CPET trended 
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towards but did not reach statistical significance at the 0.05 level, and RV LGE 
score was not significantly associated. 
Table 6-2 Prediction of a composite endpoint of atrial arrhythmia, sustained ventricular 
tachycardia, device insertion, or hospitalisation with heart failure after index CMR scan 
 Adverse events N = 11  (9.6%) 
Hazard ratio 95% confidence 
intervals 
P 
RV LGE score 1.238 0.928 - 1.65 0.146 
LV LGE mass % 1.345 1.035 - 1.749 0.027 
RVEDVi 1.013 1.006 - 1.020 <0.001 
RVEF 0.933  0.874 - 0.997 0.039 
LVEDVi 1.032 1.017 - 1.047 <0.001 
LVEF 0.934 0.890 - 0.981 0.006 
Male gender 2.156 0.571 - 8.134 0.257 
Age at repair 0.997 0.846 - 1.175 0.971 
Age at scan 1.073 1.023 - 1.124 0.004 
Number prior 
redo 
sternotomies 
 
 
1.837 
 
 
0.857 - 3.939 
 
 
0.118 
Transannular 
patch 
 
0.464 
 
0.099 - 2.188 
 
0.332 
ECG QRSi  
1.024 
 
0.997 - 1.053 
 
0.083 
NYHA class 3.987 1.325 - 11.993 0.014 
Peak VO2 % 
predicted 
 
0.966 
 
0.922 - 1.012 
 
0.146 
Peak HR % 
predicted 
 
0.934 
 
0.884 - 0.986 
 
0.014 
VE/VCO2 slope 1.066 0.957 - 1.188 0.245 
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Table 6-3 Prediction of a composite endpoint of atrial arrhythmia, sustained ventricular 
tachycardia, device insertion, or hospitalisation with heart failure after index CMR scan, 
adjusting for age at scan as a covariate 
Variable Adverse events N = 11  (9.6%) 
Hazard ratio 95% confidence 
intervals 
P 
RV LGE score 1.003 0.742 - 1.357 0.982 
Age at scan 1.072 1.015 - 1.132 0.012 
 
LV LGE mass % 1.293 0.980 - 1.706 0.070 
Age at scan 1.085 1.028 - 1.144 0.003 
 
RVEDVi 1.011 1.004 - 1.018 0.002 
Age at scan 1.065 1.015 - 1.118 0.011 
 
RVEF 0.924 0.865 - 0.987 0.002 
Age at scan 1.083 1.029 - 1.139 0.020 
 
LVEDVi 1.027 1.012 - 1.041 < 0.001 
Age at scan 1.061 1.008 - 1.117 0.023 
 
LVEF 0.939 0.893 - 0.988 0.015 
Age at scan 1.066 1.018 - 1.116 0.006 
 
Number redo 
sternotomies 
2.201 1.022 - 4.740 0.044 
Age at scan 1.083 1.028 - 1.140 0.002 
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ECG QRSi 1.020 0.994 - 1.047 0.132 
Age at scan 1.057 0.995 - 1.123 0.075 
 
NYHA class 5.377 1.606 - 18.004 0.006 
Age at scan 1.081 1.022 - 1.144 0.007 
 
Peak VO2 % 
predicted 
0.939 0.887 - 0.993 0.028 
Age at scan 1.128 1.054 - 1.207 0.001 
 
Peak HR % 
predicted 
0.951 0.898 - 1.007 0.086 
Age at scan 1.084 1.024 - 1.147 0.006 
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6.4 Discussion 
 
6.4.1 Presence and extent of LGE in repaired TOF 
 The amount of LGE seen in the RV was relatively low in most patients, and 
almost exclusively consigned to the insertion points of the RV on to the LV, and 
sites of surgical intervention, namely the RVOT and site of VSD patch repair. This is 
similar to that reported previously (Babu-Narayan et al., 2006), and is possibly due 
to increased haemodynamic stress from RV volume in the case of the RV insertion 
points. With the exception of a small number of outliers who had suffered 
myocardial infarcts the amount of LV LGE was also low with a median value of 
1.75% (IQR 0.7 - 3.23%).  
The was a weak relationship between the quantity of RV LGE seen and older age at 
surgery, older age at time of scan, and repair in an earlier surgical era. There was 
also a weak relationship between the LV LGE mass, and age at the time of scan 
and age at repair. These findings are perhaps not unexpected. Patients who 
underwent surgical repair in the 1960s and 1970s typically underwent repair of the 
defects through right ventriculotomy, and did not benefit from more modern 
techniques of myocardial preservation. From the 1980s onwards the preferred 
technique for repair was a combined transatrial and transpulmonary approach, 
with no direct incision over the free wall of the RV. This suggests that ventricular 
fibrosis may be associated with transventricular approach and earlier techniques of 
myocardial protection. 
There was a weak but significant inverse correlation between RV LGE and RVEF, 
implying that increased fibrosis of the RV is associated with reduced stroke volume 
and RV systolic impairment. On the other hand, regarding the LV, whilst there was  
a positive correlation between LV LGE and indexed LV end diastolic volume, no 
corresponding inverse correlation between LV LGE and LVEF was seen, This 
perhaps suggests that LV fibrosis may be associated with an increase in LV end 
diastolic volume initially, with an increase in end systolic volumes and reduction in 
LVEF occurring later on, i.e. too late to be seen in this cohort over the specified 
follow-up period. Further work would be required to confirm this hypothesis, 
although it is well documented that LV dysfunction is typically a very late 
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complication in repaired TOF (Apitz et al., 2009), and, as a relatively young 
cohort, this study population may therefore have been too "healthy" to display this 
relationship in its entirety. The overall impression of all of the above however, is 
that the amount of LGE is associated with a more dysfunctional ventricle, and this 
reinforces findings from previous work (Wald et al., 2009, Oosterhof et al., 2005). 
This did not however translate into a significant association with adverse markers 
of exercise performance. This is likely to be because the determinants of exercise 
performance in individuals with repaired TOF are complex, depending not just on 
ventricular volumes and contractility - which could conceivably be affected by LGE 
as a marker of ventricular fibrosis - but also factors such as heart rate response, 
minute ventilation, and abnormalities of gas exchange. Furthermore, it was not 
possible to adjust for baseline levels of training and fitness in individuals in this 
cohort, and so varying degrees of physical deconditioning may also have had an 
effect. Thus LGE in isolation is not likely to prove particularly useful in this regard.  
 
6.4.2 Use of LGE to identify patients at higher risk of adverse outcomes in 
comparison to other parameters derived from CMR and CPET 
 LV LGE mass, but not RV LGE score, was predictive of an adverse outcome 
over the follow-up period at the 0.05 level in a univariate model (Table 3), and 
interestingly this finding has been also shown by other groups when assessing 
myocardial fibrosis via the quantification of ECV: Chen and colleagues found that 
in a group of 84 TOF survivors greater LV ECV, but not RV ECV, was associated with 
arrhythmia on univariate analysis, although arrhythmia in this context included not 
just atrial arrhythmia and sustained VT but also frequent ventricular ectopy and 
non-sustained VT (Chen et al., 2016). Broberg and colleagues looked exclusively at 
LV ECV in a smaller, older group of 48 TOF survivors, and over a follow-up period 
of 3.5 +/- 1.5 years reported that of the patients with extensive LV ECV (defined 
as a fraction >30%), 5/15 experienced the adverse outcome of atrial arrhythmia (3) 
or death (2), whereas only 2/37 patients experienced atrial arrhythmia in the low 
LV ECV group, with no deaths (Broberg et al., 2016). This is contrast to the 2006 
paper where RV LGE did predict arrhythmia (Babu-Narayan et al., 2006). The 
reason that RV LGE score, and indeed RV ECV, have not been shown to be 
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predictive of an adverse outcome since is unclear. There will clearly be a birth 
cohort effect with the 2006 paper including older patients, furthermore it is 
difficult to accurately quantify the extent of abnormal areas of enhancement in 
the thin-walled RV to the same degree of precision as the LV at 1.5 Tesla.   
Another key issue to bear in mind is that when a bivariate analysis was performed - 
adjusting for age at the time of initial surgical repair - LV LGE mass trended 
towards but did not reach the 0.05 level of significance as a predictor of an 
adverse clinical outcome (Table 4). This is in contrast to other, more established 
makers of a poor prognosis in repaired TOF such as indexed RVEDV, LVEF, NYHA 
class and peak oxygen uptake on cardiopulmonary exercise testing which did 
achieve this level of statistical significance in this cohort. Again this does bring 
into question the clinical utility of LGE in TOF. 
 
6.4.3 Limitations 
 When interpreting these findings a number of limiting factors need to be 
taken into account. This was a single centre study and included a heterogeneous 
group of patients. Despite being larger than other published studies of TOF 
patients undergoing CMR, this cohort was still relatively small and patients 
experienced a low number of primary outcome events, preventing multivariable 
analysis. Patients who had already received a pacemaker before they could 
undergo CMR scanning were by definition excluded, and they could well have been 
in a higher risk group, thus giving rise to selection bias. The semiquantitative 
means of estimating RV LGE is likely to  be inferior to a formal quantification of RV 
LGE mass, although as described previously the latter is technically more difficult 
to achieve. Due to the method of estimating LV LGE mass from the short axis stack 
it was not possible to quantify any areas of LGE at the apex of the LV, as 
exemplified by some older patients who underwent insertion of a transmural apical 
vent at the time of surgery - however the amount of LGE here was likely to be 
negligible in terms of absolute quantity. Finally the administration of Gadolinium 
contrast was not repeated in follow up scans for the vast majority of patients, and 
so it was not possible to determine whether the amount of LGE increases over time 
and whether rate of change is more significant than the absolute value. However, 
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given the small amounts of LGE seen overall, it is likely that a large time interval 
would be required to see any significant difference. It was necessary to exclude 
patients who had already experienced an adverse outcome at the time of scan 
from the survival analysis; therefore as with other, similar, studies, the data is 
subject to the problem of left censoring.  
 
6.4.4 Conclusion 
 In summary, in a contemporary cohort of patients with repaired TOF, the 
amount of LGE is lower in younger patients who underwent repair at an earlier 
age. LGE is rarely seen outwith the sites of surgical repair or the insertion points of 
the RV on to the LV. It is associated with other markers of ventricular dysfunction 
such as increased volume and reduced ejection fraction, but not exercise 
performance. The data presented here suggest that LV myocardial fibrosis as 
quantified by LGE is useful as a univariate predictor of adverse outcomes in 
contemporary adult survivors of TOF. However the data does not allow the 
construction of a robust multivariable model, and in view of the low incidence of 
hard clinical endpoints in this patient group, it is clear that only a large, 
prospective, multicentre study with follow up for a much longer period of time 
would achieve this. If this data can be obtained then the risk of ventricular 
arrhythmia, heart failure hospitalisation, and death can be more formally 
quantified, thus helping to guide clinical decision making and perhaps allow the 
creation of a formal risk scoring system. 
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Chapter 7 Discussion  
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7.1 Summary of findings 
 
 Chapter 3 summarised the results of a review of a total of 41 papers relating 
to patients with a systemic RV and repaired TOF. I confirmed that mortality is 
higher for those patients with a systemic RV, and of those patients with a systemic 
RV mortality is worse in CCTGA when compared to TGA-atrial switch. Survival to 30 
years from baseline (generally taken as the date of initial surgical repair) for 
repaired TOF and TGA-atrial switch was relatively good at 86% and 78% 
respectively, but for CCTGA the equivalent figure was only 51% (see Table 3.5 and 
Figure 3.2). The only consistent risk factor for mortality identified was earlier birth 
cohort / earlier surgical era, although a transannular patch repair was also 
identified as conferring a worse prognosis for patients with repaired TOF by three 
papers. No differences in gender were reported. Geographical variation within 
countries (and urban versus rural split) was not assessed by any paper I reviewed, 
however at an international level cohorts from East Asia reported the highest 
cumulative survival for all diagnostic groups. No studies assessed for the effect of 
socioeconomic status.  Unfortunately with the exception of reintervention 
morbidity outcomes and functional status were barely reported, despite their clear 
importance to any patient living with one of these conditions. And even with 
reintervention, outcomes were often simply reported as a cross-sectional analysis 
or "snapshot" at the end of the study period, rather than cumulative survival, and 
so estimates tended to vary considerably. Rates of reintervention tended to be 
much higher in the more contemporary papers; in the earliest cohorts the mean 
age of adult patients with these diagnoses was still low and therefore they had not 
had time to develop some of the later sequelae of their respective diagnoses. 
 Chapters 4 and 5 describe my own analysis of data relating to cohorts of 
patients with systemic RV and repaired TOF respectively. This is the first time 
mortality and morbidity in a contemporary, nationwide population of ACHD 
patients in Scotland has been reported. 
 I confirmed that the finding of a higher mortality in SRV patients versus TOF 
patients appears to apply to Scotland as well, both by using the Kaplan Meier 
technique to assess cumulative survival, and also by calculating the appropriate 
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SMRs  (Figure 7.1). The SMRs I obtained for the Scottish cohort were similar to 
those obtained by the only other study I identified which reported SMRs for these 
groups of ACHD patients in a large tertiary centre elsewhere in the UK (Diller et 
al., 2015).  
 Within the SRV cohort, patients with CCTGA did not appear to fare as badly 
with respect to TGA-atrial switch patients as they did in the papers identified in 
the literature review. By log rank test there was no significant difference in 
cumulative survival between these two groups, and furthermore the 95% 
confidence interval estimates of SMR overlapped considerably. Clearly it would be 
impossible to conclusively identify why this is the case - at least without comparing 
patient-level data between all of the studies - however the most obvious 
hypothesis would be that the other CCTGA papers all included childhood mortality, 
and therefore would have included children with the most severe forms of CCTGA 
with multiple associated structural lesions who would have been less likely to 
survive to adulthood. 
 Within the TOF cohort cumulative mortality was relatively low, however in a 
multivariable model increased RVEDV at baseline, older age at repair, and female 
gender appeared to confer a higher risk of a composite outcome of death and 
arrhythmia.  
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Figure 7.1: Comparison of SMR between patients with a systemic RV and patients 
with repaired TOF 
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 When morbidity outcomes for the SRV group are compared to the TOF group 
it becomes apparent that crude event rates (expressed as per 100 years of patient 
follow-up) appear to be higher in the TOF group for arrhythmia and reintervention 
(Table 7.1). The former appears to be driven largely by the fact that no ventricular 
arrhythmia was documented in the SRV group at all (although presumably as this 
group ages and more patients develop severe SRV dysfunction this will change), 
the latter by the sheer number of PVRs performed in the TOF group. Raw data such 
as this needs does need to be interpreted with caution however, as clearly the 
baseline reference point was not the same for each group, and clearly the values 
obtained will take no account of outcomes that occurred before the follow-up 
period. 
 When functional status is compared, this was ostensibly better in the TOF 
cohort. Almost 97% of TOF patients were in NYHA class 1 compared to 67% in the 
SRV cohort. This relationship was confirmed by those patients who underwent 
CPET assessment: peak VO2 as a percentage of the predicted value was higher, and 
the VE/VCO2 slope was lower in the TOF cohort compared to the SRV cohort (69% 
versus 66%, and 36 versus 33 respectively, in keeping with results published 
elsewhere (Diller et al., 2005, Dimopoulos et al., 2006). This lends support to the 
hypothesis that a morphological RV is less well adapted to support the 
physiological demands of exercise compared to a morphological LV. Prescribing of 
cardiac medication in both cohorts was low. The commonest class of drug 
prescribed in patients with a systemic RV was an ACE inhibitor / A2RB (16% of TGA-
atrial switch and 19% of CCTGA patients), whereas in the TOF cohort it was a 
betablocker - mainly for those patients who had experienced arrhythmia. 
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Table 7-1 Crude incidence of adverse outcomes in patients with a systemic RV and 
patients with repaired TOF 
Outcome SRV   TOF   
 N 
events 
Person y 
follow-up 
Event rate 
per 100 
person y 
N 
events 
Person y 
follow-up 
Event rate 
per 100 
person y 
Death 7 1559.7 0.45 7 1248.7 0.56 
Arrhythmia (any) 21 1361.4 1.54 35 1069.7 3.27 
Ventricular 
arrhythmia 
0 N/A N/A 14 1206.4 1.16 
Atrial arrhythmia 21 1361.4 1.54 25 1162.1 2.15 
Cardiac device17 17 1311.6 1.30 16 1203.6 1.33 
Reintervention 22 1109.1 1.98 70 1025.4 6.79 
 
 Regarding morbidity outcomes within the SRV group, patients with CCTGA 
tended to experience less arrhythmia and less reintervention after the baseline of 
18 years, but a higher incidence of pacemaker implantation. Again one can only 
speculate as to the pathophysiological mechanisms underpinning this observation, 
but the greater rates of arrhythmia and reintervention in the TGA-atrial switch 
group may well have been driven by the fact that by definition the interatrial 
baffles create scar which leads to electrical re-entry (and hence arrhythmia), and 
also creates the propensity for stenosis and leaks (which drives the need for 
reintervention). In CCTGA patients anatomy of the AV node is variable, and VSD is 
more frequent - both of these factors can result in AV block. 
 The final results chapter, chapter 6, looked at the role of cardiac MRI in 
more detail, specifically with regard to establishing prognosis in repaired TOF. To 
my knowledge this is the largest published series to formally quantify the degree 
of myocardial fibrosis (as measured by LGE) in the LV and RV, and it showed that 
increased fibrosis was associated with adverse clinical outcomes, although the 
                                                            
17 Includes pacemaker, CRT, and ICD implantation 
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relatively small number of clinical events in the follow up period made it difficult 
to quantify the nature of this relationship by means of a multivariable analysis.  
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7.2 Limitations 
 
 Ultimately this was a single centre retrospective study, with all the inherent 
limitations that this entails. Mortality was low, and this made it difficult to create 
a robust multivariable model to identify those patients at higher risk of death. 
Following the literature review it became apparent that almost all of the other 
published literature was subject to the same problem, and owing to the wide 
variety of ways in which criteria for study entry were specified and clinical 
outcomes were reported, it would be impossible to carry out a robust meta-
analysis to address this. Another problem arises when trying to define the baseline 
characteristics for the population of interest, specifically with regards to the 
actual operations undertaken. There are a daunting number of different codes for 
the various types of congenital cardiac surgery which may be performed, and even 
if these are entered correctly it may be impossible to try and summarise them in a 
meaningful way without reference to the original operation note. Actual operation 
notes are only readily available from the digital era of medical records i.e. after 
2007-2008, and prior to this one is faced with the prospect of trying to unearth the 
original paper based health records, sourcing them from a wide variety of different 
centres and trying to account for the fact that there may be no standardised 
unique patient identification number from that era, and that patent's names may 
have changed in the interim. This leads on to the wider problem of missing data 
for a host of investigations and clinical outcomes, and how there is a pressing need 
for this to be improved. Finally, although I collected general data regarding 
Carstairs deprivation scores for the TOF cohort, I did not gather specific data 
regarding educational attainment and employment status - arguably this would 
provide a more nuanced assessment of socioeconomic status in these patients, in 
addition to being an outcome which is poorly reported in the literature. 
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7.3 Clinical implications and future directions for research 
 
 The ever expanding population of adults with congenital heart disease 
represents a major challenge to the National Health Service in Scotland, with a 
high level of morbidity that is not easy to manage even with a comprehensive (and 
expensive) range of cardiac investigations, procedures and operations. All of the 
above suggests that we need larger numbers of patients, standardised reporting of 
baseline characteristics and patient outcomes, and prospective rather than 
retrospective follow up. Perhaps the best way of achieving this would either be 
through the creation of a national or international registry. Whilst the Central 
Cardiac Audit Database (CCAD) reports outcomes for surgical or percutaneous 
procedures in a standardised way for ACHD patients throughout the UK, the data 
focuses primarily on 30-day mortality. Far more powerful would be a registry with 
clearly defined entry criteria for each particular congenital cardiac diagnosis, 
uniform outcome reporting, case linkage to other national registries such as births, 
deaths and acute hospital admissions, and regular uploading of data derived from 
ECG, CMR and CPET for each patient. The sheer volume of data generated from 
such a program would make it very easy to identify multivariable predictors of 
mortality and morbidity, document trends in survival over time, and allow the 
creation of a risk scoring system for specific diagnoses or adverse outcomes. This 
would also allow data to be collected on the "milder" forms of congenital heart 
disease such as bicuspid aortic valve and small VSDs, where as described previously 
patients may not come through the national centre. This is important because 
these patients form a much larger cohort as a whole, and their prognosis, whilst 
better than for the moderate and great complexity lesions, is still worse than the 
general population and not as benign as previously assumed (Videbæk et al., 
2015). Yet another advantage of such a system is that it would automatically 
highlight which patients had not undergone key tests such as cardiac MRI and 
CPET, thus prompting the clinical team to investigate why - e.g. is there a large 
proportion of patients who are genuinely unable to undergo these tests, does 
capacity need to be expanded, and so on. And finally it would be possible to design 
and test simple clinical scoring systems which may identify which patients could be 
at higher risk for adverse outcomes, or who might benefit most from a particular 
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intervention or therapy. This has recently been applied to a large multicentre 
cohort of patients undergoing catheter-based intervention (Stefanescu et al., 
2017), but given sufficient patient numbers similar systems could readily be 
applied to specific diagnostic groups or those patients undergoing a specific 
procedure e.g. PVR. 
The issue to consider is how mortality and morbidity is reported. For reasons 
discussed earlier, cumulative survival from baseline using the Kaplan Meier 
method, whilst useful, is not as generalisable as reporting a standardised mortality 
ratio. Could morbidity outcomes be reported in the same way - as standardised 
morbidity ratios - when compared to the general Scottish population? Whilst this 
would not necessarily be applicable for very specialised outcomes such as PVR, it 
would certainly be relevant for other more widely reported cardiovascular 
outcomes such as stroke, myocardial infarction, heart failure, and endocarditis, 
and if this could be re-assessed at regular intervals (say every 2-3 years) it would 
provide a useful barometer as to whether the ACHD population as a whole is 
getting sicker or healthier, and also identify where the clinical need for 
preventative medicine is greatest for these patients.  
With regard to assessing the clinical efficacy and cost effectiveness of an 
intervention such as PVR, the best way forward would be through the creation of a 
multicentre randomised control trial - perhaps using different thresholds for when 
to intervene. However this would be difficult - there would need to be some way 
of standardising patients by entry criteria, furthermore there would likely need to 
be at least several years worth of follow-up to show a meaningful difference in 
hard clinical outcomes rather than surrogate endpoints such as change in RV 
volumes. 
Lastly I have shown that variation in outcomes by gender, socioeconomic status 
and geographical region are rarely reported. Whilst the Scottish data suggests that, 
at least for adult survivors of TOF, socioeconomic status is comparable to the 
general population, there is a suggestion that female patients may do worse when 
RVEDV is taken into account, and clearly these factors are worthy of dedicated 
study. 
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7.4 Conclusion 
 
In this thesis I have demonstrated to the reader just how much uncertainty there is 
in establishing long term prognosis in ACHD, and how much of what might be 
regarded as routine clinical data is manifestly absent from the results reported by 
many congenital cardiac centres across the world. Retrieving and analysing the 
data in the course of this project has been a useful exercise, and has not just 
allowed the detailed characterisation of outcomes in two large, contemporary, 
national ACHD cohorts in Scotland, but also  provided insight into how this can be 
achieved more efficiently and effectively. I have identified significant areas where 
knowledge gaps exist, and suggested ways in which these might be addressed. All 
of the above will hopefully allow us to identify where the areas of greatest clinical 
need are in ACHD, and where we might make the most significant contributions to 
improving the outlook for this important, complex group of patients.    
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